WO2022103280A1 - Methanogen inhibitors - Google Patents
Methanogen inhibitors Download PDFInfo
- Publication number
- WO2022103280A1 WO2022103280A1 PCT/NZ2021/050199 NZ2021050199W WO2022103280A1 WO 2022103280 A1 WO2022103280 A1 WO 2022103280A1 NZ 2021050199 W NZ2021050199 W NZ 2021050199W WO 2022103280 A1 WO2022103280 A1 WO 2022103280A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- formula
- mmol
- nmr
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract description 10
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 claims abstract description 106
- 241000282849 Ruminantia Species 0.000 claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 claims abstract description 26
- 210000004767 rumen Anatomy 0.000 claims abstract description 19
- 150000001875 compounds Chemical class 0.000 claims description 142
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 99
- 239000000203 mixture Substances 0.000 claims description 49
- 150000003839 salts Chemical class 0.000 claims description 35
- 229910004679 ONO2 Inorganic materials 0.000 claims description 34
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000001424 substituent group Chemical group 0.000 claims description 16
- 230000015572 biosynthetic process Effects 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 230000001079 digestive effect Effects 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 235000010755 mineral Nutrition 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 229920006395 saturated elastomer Polymers 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 4
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 4
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000000460 chlorine Substances 0.000 claims description 3
- 229910052801 chlorine Inorganic materials 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 239000005864 Sulphur Substances 0.000 claims description 2
- 235000019486 Sunflower oil Nutrition 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003270 Vitamin B Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000654 additive Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 239000003674 animal food additive Substances 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 2
- 229960001231 choline Drugs 0.000 claims description 2
- 239000010941 cobalt Substances 0.000 claims description 2
- 229910017052 cobalt Inorganic materials 0.000 claims description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 2
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000003792 electrolyte Substances 0.000 claims description 2
- 235000019152 folic acid Nutrition 0.000 claims description 2
- 239000011724 folic acid Substances 0.000 claims description 2
- 229960000304 folic acid Drugs 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 239000011777 magnesium Substances 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- 235000018102 proteins Nutrition 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960002477 riboflavin Drugs 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000002600 sunflower oil Substances 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000019156 vitamin B Nutrition 0.000 claims description 2
- 239000011720 vitamin B Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000005282 vitamin D3 Nutrition 0.000 claims description 2
- 239000011647 vitamin D3 Substances 0.000 claims description 2
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 235000012711 vitamin K3 Nutrition 0.000 claims description 2
- 239000011652 vitamin K3 Substances 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940045999 vitamin b 12 Drugs 0.000 claims description 2
- 229940011671 vitamin b6 Drugs 0.000 claims description 2
- 229940021056 vitamin d3 Drugs 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical group C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- UGQZLDXDWSPAOM-UHFFFAOYSA-N pyrrolo[3,4-f]isoindole-1,3,5,7-tetrone Chemical class C1=C2C(=O)NC(=O)C2=CC2=C1C(=O)NC2=O UGQZLDXDWSPAOM-UHFFFAOYSA-N 0.000 abstract description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 156
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 143
- 239000007787 solid Substances 0.000 description 126
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 122
- 239000011541 reaction mixture Substances 0.000 description 99
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 90
- 238000005160 1H NMR spectroscopy Methods 0.000 description 83
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 79
- 238000001816 cooling Methods 0.000 description 58
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 52
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 52
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 51
- 235000019439 ethyl acetate Nutrition 0.000 description 49
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 47
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 46
- 239000012258 stirred mixture Substances 0.000 description 44
- 238000001914 filtration Methods 0.000 description 42
- 238000000746 purification Methods 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 33
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 32
- 238000010992 reflux Methods 0.000 description 31
- 229910017604 nitric acid Inorganic materials 0.000 description 30
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 29
- -1 cofactors Chemical class 0.000 description 27
- 239000004202 carbamide Substances 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 25
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 23
- 235000019341 magnesium sulphate Nutrition 0.000 description 23
- 239000003208 petroleum Substances 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 20
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 20
- 229930040373 Paraformaldehyde Natural products 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 229920002866 paraformaldehyde Polymers 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 10
- 229940125797 compound 12 Drugs 0.000 description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- 125000001072 heteroaryl group Chemical group 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 125000005842 heteroatom Chemical group 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002480 mineral oil Substances 0.000 description 6
- 235000010446 mineral oil Nutrition 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 239000012312 sodium hydride Substances 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- VLDPXPPHXDGHEW-UHFFFAOYSA-N 1-chloro-2-dichlorophosphoryloxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(Cl)=O VLDPXPPHXDGHEW-UHFFFAOYSA-N 0.000 description 5
- 241001494479 Pecora Species 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000029058 respiratory gaseous exchange Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 5
- KQIGMPWTAHJUMN-VKHMYHEASA-N 3-aminopropane-1,2-diol Chemical compound NC[C@H](O)CO KQIGMPWTAHJUMN-VKHMYHEASA-N 0.000 description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- WKVSEJXEIVEFJT-UHFFFAOYSA-N bromo ethanesulfonate Chemical compound CCS(=O)(=O)OBr WKVSEJXEIVEFJT-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 238000000099 in vitro assay Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- ZYZCALPXKGUGJI-DDVDASKDSA-M (e,3r,5s)-7-[3-(4-fluorophenyl)-2-phenyl-5-propan-2-ylimidazol-4-yl]-3,5-dihydroxyhept-6-enoate Chemical compound C=1C=C(F)C=CC=1N1C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C(C)C)N=C1C1=CC=CC=C1 ZYZCALPXKGUGJI-DDVDASKDSA-M 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 2
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 2
- KJJPLEZQSCZCKE-UHFFFAOYSA-N 2-aminopropane-1,3-diol Chemical compound OCC(N)CO KJJPLEZQSCZCKE-UHFFFAOYSA-N 0.000 description 2
- CYWGSFFHHMQKET-UHFFFAOYSA-N 2-methylsulfanylethanamine Chemical compound CSCCN CYWGSFFHHMQKET-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- IUQPYUUSZJYMFG-UHFFFAOYSA-N 5-carbamoylbenzene-1,2,4-tricarboxylic acid Chemical compound NC(=O)C1=CC(C(O)=O)=C(C(O)=O)C=C1C(O)=O IUQPYUUSZJYMFG-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 241000203069 Archaea Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 2
- 241000282994 Cervidae Species 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241000209082 Lolium Species 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 2
- FTQJPVISZZTLLB-UHFFFAOYSA-N [O-][N+](OCN(C(C(C1=C2)=CC(C(N3C4=NC=CC=C4)=O)=C2C3=O)=O)C1=O)=O Chemical compound [O-][N+](OCN(C(C(C1=C2)=CC(C(N3C4=NC=CC=C4)=O)=C2C3=O)=O)C1=O)=O FTQJPVISZZTLLB-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125961 compound 24 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940125851 compound 27 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 2
- JWDZKPSFIPANKC-UHFFFAOYSA-N (1-benzyltetrazol-5-yl)methanamine Chemical compound NCC1=NN=NN1CC1=CC=CC=C1 JWDZKPSFIPANKC-UHFFFAOYSA-N 0.000 description 1
- DZOYBHYRCNYUFV-UHFFFAOYSA-N (1-ethyltetrazol-5-yl)methanamine Chemical compound CCN1N=NN=C1CN DZOYBHYRCNYUFV-UHFFFAOYSA-N 0.000 description 1
- SQVYHZOAHYEQME-UHFFFAOYSA-N (1-methyltetrazol-5-yl)methanamine Chemical compound CN1N=NN=C1CN SQVYHZOAHYEQME-UHFFFAOYSA-N 0.000 description 1
- CYAYKKUWALRRPA-UHFFFAOYSA-N (3,4,5-triacetyloxy-6-bromooxan-2-yl)methyl acetate Chemical compound CC(=O)OCC1OC(Br)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O CYAYKKUWALRRPA-UHFFFAOYSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- SKMIDTLZYXSDBU-UHFFFAOYSA-N 1-nitro-4-[(4-nitrophenoxy)methoxy]benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCOC1=CC=C([N+]([O-])=O)C=C1 SKMIDTLZYXSDBU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- WOXFMYVTSLAQMO-UHFFFAOYSA-N 2-Pyridinemethanamine Chemical compound NCC1=CC=CC=N1 WOXFMYVTSLAQMO-UHFFFAOYSA-N 0.000 description 1
- OKUWOEKJQRUMBW-UHFFFAOYSA-N 2-[2-(2-methoxyethoxy)ethoxy]ethanamine Chemical compound COCCOCCOCCN OKUWOEKJQRUMBW-UHFFFAOYSA-N 0.000 description 1
- WGQYVGMCDPUCEJ-UHFFFAOYSA-N 2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethanamine Chemical compound COCCOCCOCCOCCOCCN WGQYVGMCDPUCEJ-UHFFFAOYSA-N 0.000 description 1
- KNVRBEGQERGQRP-UHFFFAOYSA-N 2-amino-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CN KNVRBEGQERGQRP-UHFFFAOYSA-N 0.000 description 1
- WKNMKGVLOWGGOU-UHFFFAOYSA-N 2-aminoacetamide;hydron;chloride Chemical compound Cl.NCC(N)=O WKNMKGVLOWGGOU-UHFFFAOYSA-N 0.000 description 1
- MVQXBXLDXSQURK-UHFFFAOYSA-N 2-aminoethanesulfonamide Chemical compound NCCS(N)(=O)=O MVQXBXLDXSQURK-UHFFFAOYSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical compound NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- GRCLBOGXTPXNPL-UHFFFAOYSA-N 2-fluoropyridine-3-carboxamide Chemical compound NC(=O)C1=CC=CN=C1F GRCLBOGXTPXNPL-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- FERWBXLFSBWTDE-UHFFFAOYSA-N 3-aminobutan-2-ol Chemical compound CC(N)C(C)O FERWBXLFSBWTDE-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000282979 Alces alces Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000283726 Bison Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000030939 Bubalus bubalis Species 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- YCVWASPLTQRJGC-UHFFFAOYSA-N COC(C(CO)N(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O Chemical compound COC(C(CO)N(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O YCVWASPLTQRJGC-UHFFFAOYSA-N 0.000 description 1
- GKGLELDUKUQPPM-UHFFFAOYSA-N COC(CN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O Chemical compound COC(CN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O GKGLELDUKUQPPM-UHFFFAOYSA-N 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000282818 Giraffidae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- LAONMQDPOJSELF-UHFFFAOYSA-N NS(CCN(C(C(C=C1C(N2CO[N+]([O-])=O)=O)=C3C=C1C2=O)=O)C3=O)(=O)=O Chemical compound NS(CCN(C(C(C=C1C(N2CO[N+]([O-])=O)=O)=C3C=C1C2=O)=O)C3=O)(=O)=O LAONMQDPOJSELF-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- NHZQYRLCMZFBLW-UHFFFAOYSA-N OC(CN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O Chemical compound OC(CN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O NHZQYRLCMZFBLW-UHFFFAOYSA-N 0.000 description 1
- DSLNVYSPVOJBAC-UHFFFAOYSA-N OCC(CO)N(C(C(C1=C2)=CC(C(N3CO)=O)=C2C3=O)=O)C1=O Chemical compound OCC(CO)N(C(C(C1=C2)=CC(C(N3CO)=O)=C2C3=O)=O)C1=O DSLNVYSPVOJBAC-UHFFFAOYSA-N 0.000 description 1
- 231100000322 OECD 423 Acute Oral toxicity - Acute Toxic Class Method Toxicity 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241001416177 Vicugna pacos Species 0.000 description 1
- WLPLFPDMBLGNMN-UHFFFAOYSA-N [O-][N+](OCCN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O Chemical compound [O-][N+](OCCN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O WLPLFPDMBLGNMN-UHFFFAOYSA-N 0.000 description 1
- QJJMCDLOKYBBJK-UHFFFAOYSA-N [O-][N+](OCN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O Chemical compound [O-][N+](OCN(C(C(C1=C2)=CC(C(N3)=O)=C2C3=O)=O)C1=O)=O QJJMCDLOKYBBJK-UHFFFAOYSA-N 0.000 description 1
- YMQJEQTUCQDMCA-UHFFFAOYSA-N [O-][N+](OCN(C(C(C1=C2)=CC(C(N3C4=CC=CC=C4)=O)=C2C3=O)=O)C1=O)=O Chemical compound [O-][N+](OCN(C(C(C1=C2)=CC(C(N3C4=CC=CC=C4)=O)=C2C3=O)=O)C1=O)=O YMQJEQTUCQDMCA-UHFFFAOYSA-N 0.000 description 1
- UFHPAJRACOMDPT-UHFFFAOYSA-N [O-][N+](OCN(C(C(C1=C2)=CC(C(N3CC4=NC=CC=C4)=O)=C2C3=O)=O)C1=O)=O Chemical compound [O-][N+](OCN(C(C(C1=C2)=CC(C(N3CC4=NC=CC=C4)=O)=C2C3=O)=O)C1=O)=O UFHPAJRACOMDPT-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- BHELZAPQIKSEDF-UHFFFAOYSA-N allyl bromide Chemical compound BrCC=C BHELZAPQIKSEDF-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- IDNUEBSJWINEMI-UHFFFAOYSA-N ethyl nitrate Chemical compound CCO[N+]([O-])=O IDNUEBSJWINEMI-UHFFFAOYSA-N 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000005431 greenhouse gas Substances 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- COQRGFWWJBEXRC-UHFFFAOYSA-N hydron;methyl 2-aminoacetate;chloride Chemical compound Cl.COC(=O)CN COQRGFWWJBEXRC-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000000696 methanogenic effect Effects 0.000 description 1
- NDBQJIBNNUJNHA-DFWYDOINSA-N methyl (2s)-2-amino-3-hydroxypropanoate;hydrochloride Chemical compound Cl.COC(=O)[C@@H](N)CO NDBQJIBNNUJNHA-DFWYDOINSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021135 plant-based food Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/10—Feeding-stuffs specially adapted for particular animals for ruminants
Definitions
- the present invention relates to a new class of methanogen inhibitors for ruminants, in particular new pyromellitic diimide derivatives for ruminants.
- the invention also extends to the use of such derivatives in ruminants to reduce methane production in the rumen and/or to enhance productivity in the ruminant.
- Methane is produced as a natural consequence of digestion of feed by bacteria, fungi and protozoa in ruminant animals. This fermentation leads to the production of volatile fatty acids and peptides for the host. Fermentation also produces copious quantities of CO2 and H2 which are used by methanogenic archaea within the rumen to produce methane, which is ultimately released from the rumen, mostly through eructation.
- methane forming methanogens are members of the Archaea, and are quite different in a number of features compared to bacteria, fungi and protozoa. Methanogens have a number of unusual and archaeal-specific features, including cell wall structures, lipids, cofactors, and amino acid synthesis pathways, as well as their signature energy metabolism that is linked to methane production. They represent only about 1-4% of the rumen microbial community. It is known that, due to the unique metabolic pathways of methanogens and their low numbers, methanogen- specific inhibitors can be developed that do not adversely affect the fermentation of feed.
- methane loss represents a loss of energy for the ruminant. It has been previously recognised that if one could inhibit or reduce the release of methane from ruminants that the impact of methane on the environment and atmosphere would be reduced and productivity gains might be achieved in the ruminants.
- the present disclosure provides a compound of Formula I Formula I wherein R 1 is selected from -H, -alkyl, -alkyl-ONO2, or -ONO2; wherein X is different to R 1 and is selected from -H, -alkyl- ONO2, -ONO2 or a substituent of Formula II, Formula II wherein each n is independently selected from 0, 1, 2, 3, 4, 5 or 6 and when n is 0, 1, 2, 3, 4, 5, 6 any adjacent carbons are optionally unsaturated to form a double or triple bond, wherein R 2 is selected from -H, -alkyl, - alkyl-ONO2, -aryl, -heteroaryl or -heterocyclyl, - CO2R 3 ; wherein -R 1 and -R 2 together form an optionally substituted aliphatic ring which is optionally saturated; wherein -Z is selected from -H, -alkyl, -aryl, -heteroaryl,
- Z is a substituent of Formula III Formula III wherein m is 0, 1, 2, 3 or 4, and when m is 0, 1, 2, 3 or 4, any adjacent carbons are optionally unsaturated to form a double or triple bond;
- R 4 when present is selected from -H, -alkyl, alkyl-OH or -alkyl-ONO2;
- the compound of Formula I includes at least one -ONO2 substituent.
- the compound of Formula I Ri is -H, X is -ONO2 and Z is a compound of Formula III.
- R 4 is selected from -H or - alkyl-ONO2 and R 5 is selected from -H, -O-alkyl, -ONO2, -CO2-alkyl or aryl.
- Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -CO2R 3 ,
- p is selected from 0, or 1 ;
- R 4 when present is selected from -H, -alkyl-OH, or -alkyl-ONO 2 ;
- R 1 is -H
- X is -ONO 2
- Z is -H, -alkyl or a substituent of Formula III.
- n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
- R 1 is -H
- X is Formula II
- n is 0, 1 or 2
- Z is a substituent of Formula III and m is 0, 1 or 2.
- R 1 is -H
- X is Formula II
- R 2 is - CH 2 ONO 2
- n is 0, 1 or 2
- Z is a substituent of Formula III and m is 0, 1 or 2.
- the compound of Formula I is or a salt thereof.
- the compound of Formula I is or a salt thereof.
- the compound of Formula I is or a salt thereof. In one embodiment the compound of Formula I is or a salt thereof.
- the compound of Formula I is or a salt thereof. In one embodiment the compound of Formula I is
- the compound of Formula I is or a salt thereof. In one embodiment the compound of Formula I is o r a salt thereof.
- the compound of Formula I is or a salt thereof.
- the present invention provides the compound of Formula I as defined above for reducing the formation of methane from the digestive actions of ruminants and/or for improving ruminant performance.
- a compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants.
- a compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants by at least 10%.
- a compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants by at least 15%.
- the compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants by at least 20%.
- the present invention further provides a method for reducing the production of methane emanating from a ruminant and/or for improving ruminant animal performance, comprising administering orally to the ruminant an effective amount of at least one compound of Formula I or a salt thereof to the ruminant.
- Oral administration is to be understood as a route involving drenching, addition to feed, water source or pasture; or manual administration of a bolus or a capsule.
- the effective amount of at least one compound of Formula I or a salt thereof is administered at least once-daily to the ruminant.
- the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 10% per day. In one embodiment the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 15% per day.
- the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 20% per day.
- composition for oral administration comprising at least one compound of Formula I or a salt thereof for reducing the production of methane emanating from a ruminant, and the composition further including at least one agriculturally and orally acceptable excipient.
- composition is adapted for use as a feed additive.
- composition is adapted for use as a water additive.
- composition is adapted for use as a ruminant lick.
- composition is adapted for use as an oral drench.
- composition is adapted for use as a rumen bolus or capsule.
- composition is adapted to reduce the production of methane emanating from the ruminant by at least 10% per day.
- composition is adapted to reduce the production of methane emanating from the ruminant by at least 15% per day.
- composition is adapted to reduce the production of methane emanating from the ruminant by at least 20% per day.
- the excipient includes one or more minerals and/or one or more vitamins.
- the excipient includes one or more vitamins selected from vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3, vitamin B 12, biotin and choline, vitamin B l, vitamin B2, vitamin B6, niacin, folic acid or the like.
- the excipient includes one or more minerals selected from calcium, phosphorus, sodium, manganese, zinc, iron, copper, chlorine, sulphur, magnesium, iodine, selenium, and cobalt or the like.
- composition further includes sunflower oil, electrolytes such as ammonium chloride, calcium carbonates, starch, proteins or the like.
- the compounds of the present invention have potential for use in a ruminant to reduce the formation of methane without affecting microbial fermentation in a way that would be detrimental to the ruminant.
- ruminant as used herein is a mammal that is able to acquire nutrients from plantbased food by fermenting it in a specialized foregut (the rumen) prior to digestion, principally through microbial activity.
- Representative examples of ruminants and other foregut fermenters include cattle, goats, sheep, giraffes, bison, moose, elk, yaks, water buffalo, deer, camels, alpacas, llamas, and antelope.
- an effective amount refers to an amount of at least one compound of Formula I or a salt thereof that either reduces the production of methane emanating from the ruminant or improves ruminant performance.
- ruminant performance refers to improving the productivity of the ruminant, such as increased weight gain, milk yield or quality, wool growth or quality, surviving offspring per parturition, or the like.
- halo refers to a halogen atom selected from Cl, Br, or F.
- aliphatic ring is a cyclic organic compound containing carbon atoms joined to form a non-aromatic ring.
- the aliphatic ring is optionally substituted with alkyl, hydroxy, halo, -ONO2 or the like.
- alkyl refers to a straight or branched chain, saturated hydrocarbon having from 1 to 6 carbon atoms.
- Representative C 1 -C 6 alkyl groups include, but are not limited to methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl (eg n- pentyl), hexyl and the like.
- the C 1 -C 6 alkyl group may be further substituted with, hydroxy or aryl.
- aryl refers to “aryl”, unless specifically limited, denotes a C6-12 aryl group, suitably a C 6 - 10 aryl group, more suitably a C6-8 aryl group.
- Aryl groups will contain at least one aromatic ring (e.g. one, two or three rings). Examples of a typical aryl group with one aromatic ring is phenyl. An example of a typical aryl group with two aromatic rings is naphthyl.
- heteroaryl refers to ”, unless specifically limited, denotes an aryl residue, wherein one or more (e.g., 1, 2, 3, or 4, suitably 1, 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O, or else a 5-membered aromatic ring containing one or more (e.g., 1, 2, 3, or 4, suitably 1, 2 or 3) ring atoms selected from N, S and O.
- Exemplary monocyclic heteroaryl groups having one heteroatom include: five membered rings (e.g., pyrrole, furan, thiophene); and six membered rings (e.g., pyridine, such as pyridin-2-yl, pyridin-3-yl and pyridin-4-yl).
- five membered rings e.g., pyrrole, furan, thiophene
- six membered rings e.g., pyridine, such as pyridin-2-yl, pyridin-3-yl and pyridin-4-yl.
- Exemplary monocyclic heteroaryl groups having two heteroatoms include: five membered rings (e.g., pyrazole, oxazole, isoxazole, thiazole, isothiazole, imidazole, such as imidazol-l-yl, imidazol-2-yl imidazol-4-yl); six membered rings (e.g., pyridazine, pyrimidine, pyrazine).
- five membered rings e.g., pyrazole, oxazole, isoxazole, thiazole, isothiazole, imidazole, such as imidazol-l-yl, imidazol-2-yl imidazol-4-yl
- six membered rings e.g., pyridazine, pyrimidine, pyrazine.
- Exemplary monocyclic heteroaryl groups having three heteroatoms include: 1,2,3-triazole, 1,2,4-triazole, 1,2,3-oxadiazole, 1,2,4- oxadizole, 1,2,5-oxadizole and 1,3,4 oxadiazole, 1,2,3-thiadazole, 1,2,4-thiadazole, 1,2,5- thiadazole and 1,3,4-thiadazole.
- Exemplary monocyclic heteroaryl groups having four heteroatoms include tetrazole and optionally substituted tetrazole.
- Exemplary bicyclic heteroaryl groups include: indole (e.g., indol-6-yl), benzofuran, benzothiophene, quinoline, isoquinoline, indazole, benzimidazole, benzthiazole, quinazoline and purine.
- the heteroaryl groups may be substituted with alkyl or alkyl-aryl (such as benzyl) or aryl (such as phenyl).
- heterocyclyl as used herein includes a “carbocycle” as defined herein, wherein one or more (e.g. 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (e.g. O, N, or S).
- heterocycle or “heterocyclyl” includes saturated rings (i.e., heterocycloalkyls), and partially unsaturated rings.
- Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
- heterocycles also include by way of example and not limitation sugars such as glucose, sucrose, fructose, galactose, lactose, maltose, ribose and deoxyribose.
- Some of the crystalline forms of the compounds may exist in more than one polymorphic form and as such all forms are intended to be included in the present disclosure.
- some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this disclosure.
- the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- the present disclosure further includes within its scope prodrugs of the compounds described herein.
- prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired active compound.
- the term “administering” shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, but which converts to the above specified compound in vivo after administration to the subject.
- composition is intended to encompass a product comprising a claimed compound(s) in a therapeutically effective amount, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
- a salt thereof is a salt of an acid or a basic nitrogen atom.
- Illustrative salts include, but are not limited, to sodium salt, potassium salt, lithium salt, calcium salt, ammonium salt, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, and the like.
- the resultant crude solid was taken up in 1,2 -dichloroethane (25 mL) and was added urea (1.5 mg, 0.03 mmol), 70% nitric acid (0.07 mL, 1.11 mmol) and acetic anhydride (0.20 mL, 2.12 mmol), then heated under reflux for 4 h. After cooling to room temperature, the reaction mixture was diluted with dichloromethane (20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo.
- the resultant crude solid was taken up in 1,2 -dichloroethane (10 mL) and was added urea (0.8 mg, 0.01 mmol), 70% nitric acid (0.10 mL, 1.31 mmol) and acetic anhydride (0.25 mL, 2.63 mmol) in 1,2-dichloroethane (10 mL), then heated under reflux for 2 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo, diluted with ethyl acetate (20 mL) and washed with water (20 mL).
- 3.4-f]isoindol-2(1H)- yl)acetamide A stirred mixture of pyromellitic imide anhydride (1.00 g, 4.61 mmol) and 2-amino- N,N- dimethylacetamide (0.56 g, 5.53 mmol) in DMF (20 mL) was heated at 100 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture.
- the compounds of the present invention were initially screened for activity using an in vitro fully automated incubation system for the measurement of total gas production and gas composition (methane and hydrogen).
- the system used is described in detail in the paper by Muetzel et al. (2014; Animal Feed Science and Technology 196, 1-11).
- the system in this specification is referred to as the rumen in vitro system or RIV.
- the RIV system provides a relatively simple tool for determining the rate and production of methane and also whether the rate and production of methane is inhibited or reduced by a particular compound or feed.
- Rumen in vitro assays use rumen fluid from donor animals (typically either sheep or cattle) which is typically combined with a buffer and then incubated in sealed fermentation vessels at 39 °C for either 24 or 48 h. These assays systems have been well-characterised and used by the scientific community over the last two decades (Rymer et al. 2005). The system that has been used here to characterise the effects of inhibitors on methane production and gas production, and the formation of H 2 , was described by Muetzel et al. (2014).
- Rumen in vitro assay systems reflect what can occur in the rumen in vivo, but only short-term, due to their short incubation times (typically not exceeding 48 h) which is limited by its buffering capacity and the fact that it is a closed system.
- Stock solutions of inhibitors were re-suspended in dimethylformamide (DMF) at concentrations 1000-fold higher than the highest used for the assays. Any further dilutions were also prepared using DMF.
- the total amount of inhibitor solution added to the rumen fluidbuffer mixture (60 mL) was 60 pl.
- Incubations used 60 ml of medium containing 12 ml of filtered rumen fluid and 48 ml of buffer in serum bottles for 24-48 h, essentially as described by Muetzel et al. (2014). Two fistulated cattle were used as donor animals for rumen fluid and treatments were incubated in duplicate bottles. Sets of duplicate incubation vials that contained rye grass (with rumen fluid -buffer mixture), and rye grass with 30 pM bromoethanesulfonate (BES) were also incubated as negative and positive controls, respectively.
- BES bromoethanesulfonate
- One experiment consists of 2 replicates of an inhibitor at any one concentration run at the same time, and a run can contain up to 32 bottle, including positive (30 pM BES) and negative (no inhibitor added) controls.
- Compound 12 was tested using the 60 mL rumen in vitro assay system at 100 pM and 2 pM final concentrations and compared to a positive control with 30 pM BES. At 30 pM and 2 pM, inhibition levels were approximately 86.4 % and 16.6 % at 18 h, respectively.
- mice testing used two groups with three mice (female Swiss mice, non-pregnant), all at approximately 8-9 weeks of age. On the day of testing, food was withdrawn 1-2 hours prior to dosing. Following fasting, the animals were weighed and the test substances administered. Access to food was resumed 1-2 hours after administration of the compounds. The compounds were administered in a single dose by oral gavage in corn oil (maximum of 0.3 ml per dose) at the selected dose and the time recorded. The mice were observed individually after dosing at least once during the first 30 minutes, periodically over the first 24 hours, with special attention given to the first 4 hours, and then daily thereafter for a total of 14 days.
- mice were weighed every seven days (0, 7 and 14 days). All observations were systematically recorded for each individual animal. These observations included (if present): tremors, convulsions, salivation, diarrhoea, lethargy, sleep, coma, and changes in fur, skin, eyes, mucus membranes, respiration, motor activity and behaviour. No adverse effects were noted for Compound 12 at 300 mg/kg.
- the animals were adapted to GP diet for 14 days prior to entering the methane measurement chambers.
- Table 1 Data for 2-day dosing with Compound 12. P2 values are the average of the first and second days of dosing.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a new class of methanogen inhibitors for ruminants, in particular new pyromellitic diimide derivatives for ruminants. The invention also extends to the use of such derivatives in ruminants to reduce methane production in the rumen and/or to enhance productivity in the ruminant.
Description
METHANOGEN INHIBITORS
FIELD OF INVENTION
The present invention relates to a new class of methanogen inhibitors for ruminants, in particular new pyromellitic diimide derivatives for ruminants. The invention also extends to the use of such derivatives in ruminants to reduce methane production in the rumen and/or to enhance productivity in the ruminant.
BACKGROUND OF INVENTION
Methane is produced as a natural consequence of digestion of feed by bacteria, fungi and protozoa in ruminant animals. This fermentation leads to the production of volatile fatty acids and peptides for the host. Fermentation also produces copious quantities of CO2 and H2 which are used by methanogenic archaea within the rumen to produce methane, which is ultimately released from the rumen, mostly through eructation.
The methane forming methanogens are members of the Archaea, and are quite different in a number of features compared to bacteria, fungi and protozoa. Methanogens have a number of unusual and archaeal-specific features, including cell wall structures, lipids, cofactors, and amino acid synthesis pathways, as well as their signature energy metabolism that is linked to methane production. They represent only about 1-4% of the rumen microbial community. It is known that, due to the unique metabolic pathways of methanogens and their low numbers, methanogen- specific inhibitors can be developed that do not adversely affect the fermentation of feed.
It has been recognised that the release of such methane is deleterious for two reasons. One is that methane is a greenhouse gas and the other is that the methane loss represents a loss of energy for the ruminant. It has been previously recognised that if one could inhibit or reduce the release of methane from ruminants that the impact of methane on the environment and atmosphere would be reduced and productivity gains might be achieved in the ruminants.
It is therefore an object of the present invention to overcome the above mentioned difficulties or to at least provide the public with a useful alternative.
SUMMARY OF INVENTION
In one aspect the present disclosure provides a compound of Formula I
Formula I wherein R1 is selected from -H, -alkyl, -alkyl-ONO2, or -ONO2; wherein X is different to R1 and is selected from -H, -alkyl- ONO2, -ONO2 or a substituent of Formula II, Formula II
wherein each n is independently selected from 0, 1, 2, 3, 4, 5 or 6 and when n is 0, 1, 2, 3, 4, 5, 6 any adjacent carbons are optionally unsaturated to form a double or triple bond, wherein R2 is selected from -H, -alkyl, - alkyl-ONO2, -aryl, -heteroaryl or -heterocyclyl, - CO2R3; wherein -R1 and -R2 together form an optionally substituted aliphatic ring which is optionally saturated; wherein -Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -CO2R3, -C(=O)R3, - alkyl-OH, -(alkyl-OH)-alkyl-OH, -alkyl-(alkyl-OH)2, -alkyl-(alkyl-OH)3,
-(alkyl-O-alkyl)k, -(alkyl-O)k-L; -alkyl-(C=O)O-(alkyl-O)k-L; -alkyl-SH, -alkyl-S-alkyl, - alkyl-(S=O)-alkyl, -alkyl-(SO2)-alkyl; -alkyl-(SO2)-OH; -alkyl-(SO2)-NH2; -alkyl-(SO2)- NHalkyl, -alkyl-(SO2)-N(alkyl)2; -alkyl-(SO2)-NH(alkyl-O)k-L; -alkyl-(C=O)-NH2; -alkyl- (C=O)-NH(alkyl); -alkyl-(C=O)-N(alkyl)2; -alkyl-(C=O)-NH(alkyl-O)k-L; -alkyl heterocyclyl, wherein k isl, 2, 3, 4, 5 or 6; and wherein L is -H, -alkyl; wherein R3 is selected from -H, -alkyl, -NHalkyl, -N(alkyl)2 or -aryl with the proviso that R3 is only selected from -H, -alkyl, or aryl for -CO2R3; or
Z is a substituent of Formula III
Formula III wherein m is 0, 1, 2, 3 or 4, and when m is 0, 1, 2, 3 or 4, any adjacent carbons are optionally unsaturated to form a double or triple bond; Y is selected from -CH2-, -O-, -C(=O)- -S-, -S(=O)- , -SO2-, -NH- or N(alkyl)- p is selected from 0, or 1 ;
R4 when present is selected from -H, -alkyl, alkyl-OH or -alkyl-ONO2;
R5 when present is selected from -H, -OH, -O-alkyl, -NH2, -alkyl, -NH(alkyl), -N(alkyl)2, - ONO2, -alkyl-ONO2, -aryl, -heteroaryl, -heterocyclyl, -C(=O)R3 or - CO2R3; or or a salt thereof.
In one embodiment the compound of Formula I includes at least one -ONO2 substituent.
In one embodiment the compound of Formula I, Ri is -H, X is -ONO2 and Z is a compound of Formula III. In one embodiment in the compound of Formula III, R4 is selected from -H or - alkyl-ONO2 and R5 is selected from -H, -O-alkyl, -ONO2, -CO2-alkyl or aryl.
In one embodiment, Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -CO2R3,
-C(=O)R3; -(alkyl-O)k-L, wherein k is 1, 2, 3, 4, 5 or 6; and wherein L is -H, -alkyl; or wherein R3 is selected from H, alkyl or aryl; or Z is a substituent of Formula III
Formula III
wherein m is 0, 1, 2, 3 or 4, and when m is 0, 1, 2, 3 or 4, any adjacent carbons are optionally unsaturated to form a double or triple bond;
Y is selected from -CH2-, -O-, -(C=O) -S-, -S(=O)-,
-SO2-, -N(alkyl)-; p is selected from 0, or 1 ;
R4 when present is selected from -H, -alkyl-OH, or -alkyl-ONO2;
R5 when present is selected from -H, -OH, -NH2, -alkyl, -NH(alkyl), -N(alkyl)2, -ONO2, -- alkyl-ONO2, -aryl, -heteroaryl, -heterocyclyl, -C(=O)R3 or - CO2R3.
In one embodiment Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, - CO2R3, -C(=O)R3 -(CH2CH2O)k-L, wherein R3 can be selected from H, alkyl or aryl, wherein k is 1, 2, 3, 4, 5 or 6; and wherein L is -H, -alkyl.
In one embodiment, R1 is -H, X is -ONO2; Z is -H, -alkyl or a substituent of Formula III.
In one embodiment of the compound of Formula I, n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
In one embodiment of the compound of Formula I, R1 is -H, X is Formula II, n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
In one embodiment of the compound of Formula I, R1 is -H, X is Formula II, R2 is - CH2ONO2, n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
In one embodiment the compound of Formula I or a salt thereof is selected from one or more of the following:
In one embodiment the compound of Formula I is
or a salt thereof. In one embodiment the compound of Formula I is
or a salt thereof.
In one embodiment the compound of Formula I is or a salt thereof.
In one embodiment the compound of Formula I is
In one embodiment the compound of Formula I is
or a salt thereof. In one embodiment the compound of Formula I is or a salt thereof.
In another aspect, the present invention provides the compound of Formula I as defined above for reducing the formation of methane from the digestive actions of ruminants and/or for improving ruminant performance.
In one embodiment a compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants.
In one embodiment a compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants by at least 10%.
In another embodiment of a compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants by at least 15%.
In yet another embodiment the compound of Formula I as defined above is for reducing the formation of methane from the digestive actions of ruminants by at least 20%.
In one aspect the present invention further provides a method for reducing the production of methane emanating from a ruminant and/or for improving ruminant animal performance, comprising administering orally to the ruminant an effective amount of at least one compound of Formula I or a salt thereof to the ruminant. Oral administration is to be understood as a route involving drenching, addition to feed, water source or pasture; or manual administration of a bolus or a capsule.
In one embodiment the effective amount of at least one compound of Formula I or a salt thereof is administered at least once-daily to the ruminant.
In one embodiment the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 10% per day.
In one embodiment the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 15% per day.
In one embodiment the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 20% per day.
In a further aspect of the present invention there is provided a composition for oral administration comprising at least one compound of Formula I or a salt thereof for reducing the production of methane emanating from a ruminant, and the composition further including at least one agriculturally and orally acceptable excipient.
In one embodiment the composition is adapted for use as a feed additive.
In one embodiment the composition is adapted for use as a water additive.
In another embodiment the composition is adapted for use as a ruminant lick.
In one embodiment the composition is adapted for use as an oral drench.
In another embodiment the composition is adapted for use as a rumen bolus or capsule.
In one embodiment the composition is adapted to reduce the production of methane emanating from the ruminant by at least 10% per day.
In one embodiment the composition is adapted to reduce the production of methane emanating from the ruminant by at least 15% per day.
In one embodiment the composition is adapted to reduce the production of methane emanating from the ruminant by at least 20% per day.
In one embodiment the excipient includes one or more minerals and/or one or more vitamins.
In one embodiment the excipient includes one or more vitamins selected from vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3, vitamin B 12, biotin and choline, vitamin B l, vitamin B2, vitamin B6, niacin, folic acid or the like.
In one embodiment the excipient includes one or more minerals selected from calcium, phosphorus, sodium, manganese, zinc, iron, copper, chlorine, sulphur, magnesium, iodine, selenium, and cobalt or the like.
In one embodiment the composition further includes sunflower oil, electrolytes such as ammonium chloride, calcium carbonates, starch, proteins or the like.
The compounds of the present invention have potential for use in a ruminant to reduce the formation of methane without affecting microbial fermentation in a way that would be detrimental to the ruminant.
DETAILED DESCRIPTION OF INVENTION
DEFINTIONS
The term “ruminant” as used herein is a mammal that is able to acquire nutrients from plantbased food by fermenting it in a specialized foregut (the rumen) prior to digestion, principally through microbial activity. Representative examples of ruminants and other foregut fermenters include cattle, goats, sheep, giraffes, bison, moose, elk, yaks, water buffalo, deer, camels, alpacas, llamas, and antelope.
The term “effective amount” as used herein refers to an amount of at least one compound of Formula I or a salt thereof that either reduces the production of methane emanating from the ruminant or improves ruminant performance.
The term “ruminant performance” as used herein refers to improving the productivity of the ruminant, such as increased weight gain, milk yield or quality, wool growth or quality, surviving offspring per parturition, or the like.
The term “halo” as used herein refers to a halogen atom selected from Cl, Br, or F.
The term “aliphatic ring” is a cyclic organic compound containing carbon atoms joined to form a non-aromatic ring. The aliphatic ring is optionally substituted with alkyl, hydroxy, halo, -ONO2 or the like.
The term “alkyl” as used herein refers to a straight or branched chain, saturated hydrocarbon having from 1 to 6 carbon atoms. Representative C1-C6 alkyl groups include, but are not limited to methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, tert-butyl, pentyl (eg n-
pentyl), hexyl and the like. The C1-C6 alkyl group may be further substituted with, hydroxy or aryl.
The term “aryl” as used herein refers to “aryl”, unless specifically limited, denotes a C6-12 aryl group, suitably a C6-10 aryl group, more suitably a C6-8 aryl group. Aryl groups will contain at least one aromatic ring (e.g. one, two or three rings). Examples of a typical aryl group with one aromatic ring is phenyl. An example of a typical aryl group with two aromatic rings is naphthyl.
The term “heteroaryl” as used herein refers to ”, unless specifically limited, denotes an aryl residue, wherein one or more (e.g., 1, 2, 3, or 4, suitably 1, 2 or 3) ring atoms are replaced by heteroatoms selected from N, S and O, or else a 5-membered aromatic ring containing one or more (e.g., 1, 2, 3, or 4, suitably 1, 2 or 3) ring atoms selected from N, S and O. Exemplary monocyclic heteroaryl groups having one heteroatom include: five membered rings (e.g., pyrrole, furan, thiophene); and six membered rings (e.g., pyridine, such as pyridin-2-yl, pyridin-3-yl and pyridin-4-yl). Exemplary monocyclic heteroaryl groups having two heteroatoms include: five membered rings (e.g., pyrazole, oxazole, isoxazole, thiazole, isothiazole, imidazole, such as imidazol-l-yl, imidazol-2-yl imidazol-4-yl); six membered rings (e.g., pyridazine, pyrimidine, pyrazine). Exemplary monocyclic heteroaryl groups having three heteroatoms include: 1,2,3-triazole, 1,2,4-triazole, 1,2,3-oxadiazole, 1,2,4- oxadizole, 1,2,5-oxadizole and 1,3,4 oxadiazole, 1,2,3-thiadazole, 1,2,4-thiadazole, 1,2,5- thiadazole and 1,3,4-thiadazole. Exemplary monocyclic heteroaryl groups having four heteroatoms include tetrazole and optionally substituted tetrazole. Exemplary bicyclic heteroaryl groups include: indole (e.g., indol-6-yl), benzofuran, benzothiophene, quinoline, isoquinoline, indazole, benzimidazole, benzthiazole, quinazoline and purine. The heteroaryl groups may be substituted with alkyl or alkyl-aryl (such as benzyl) or aryl (such as phenyl).
The term “heterocyclyl” as used herein includes a “carbocycle” as defined herein, wherein one or more (e.g. 1, 2, 3, or 4) carbon atoms have been replaced with a heteroatom (e.g. O, N, or S). The terms “heterocycle” or “heterocyclyl” includes saturated rings (i.e., heterocycloalkyls), and partially unsaturated rings. Substituted heterocyclyls include, for example, heterocyclic rings substituted with any of the substituents disclosed herein including carbonyl groups.
Examples of heterocycles also include by way of example and not limitation sugars such as glucose, sucrose, fructose, galactose, lactose, maltose, ribose and deoxyribose.
All possible stereoisomers of the claimed compounds are included in the present disclosure. Where a compound described herein has at least one chiral center, it may accordingly exist as enantiomers. Where a compound possesses two or more chiral centers it may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present disclosure.
Some of the crystalline forms of the compounds may exist in more than one polymorphic form and as such all forms are intended to be included in the present disclosure. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this disclosure. The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
The present disclosure further includes within its scope prodrugs of the compounds described herein. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired active compound. Thus, in these cases, the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, but which converts to the above specified compound in vivo after administration to the subject.
As used herein, the term “composition” is intended to encompass a product comprising a claimed compound(s) in a therapeutically effective amount, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
The term “or a salt thereof,” as used herein, is a salt of an acid or a basic nitrogen atom. Illustrative salts include, but are not limited, to sodium salt, potassium salt, lithium salt, calcium salt, ammonium salt, sulfate, citrate, acetate, oxalate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, and the like.
Methods of making the Compounds of Formula I
The following compounds were prepared as follows:
(l,3,5,7-Tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate
To a stirred mixture of pyromellitic diimide (1.00 g, 4.63 mmol) in DMF (100 mL) was added paraformaldehyde (0.11 g, 3.70 mmol), and the reaction mixture heated at 80 °C for 18 h, before evaporating to dryness to afford crude 2-(hydroxymethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone, which was used directly in the next step. The resultant crude solid was taken up in 1,2-dichloroethane (10 mL) and was added urea (1.8 mg, 0.03 mmol), 70% nitric acid (0.10 mL, 1.52 mmol) and acetic anhydride (0.29 mL, 3.05 mmol) in 1,2- dichloroethane (10 mL), then heated under reflux for 4 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. Purification by flash column chromatography (CH2C12/acetone, 19:1) afforded Compound 1 as a colourless solid (0.16 g, 0.53 mmol, 11% over two steps). 1H NMR (500 MHz, d6-DMSO) δ 6.03 (2H, s), 8.24 (2H, s), 11.89 (1H, s); 13C NMR (125 MHz, d6-DMSO) δ 67.6 (CH2), 117.8 (CH), 136.6 (C), 138.3 (C), 164.8 (C), 167.5 (C).
(6-Methyl-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate (Compound 2)
A stirred mixture of 2-(hydroxymethyl)-6-methylpyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)- tetraone (0.41 g, 1.58 mmol), urea (5.0 mg, 0.83 mmol), 70% nitric acid (0.25 mL, 3.95 mmol) and acetic anhydride (0.75 mL, 7.95 mmol) in 1,2 -dichloroethane (20 mL) was heated under reflux for 3 h. After cooling to room temperature, the solids were collected by filtration, washed with CH2CI2 (20 mL) and water (20 mL), then dried in vacuo to afford Compound 2 as a colourless solid (0.23 g, 0.75 mmol, 48%). 1H NMR (400 MHz, d6-DMSO) δ 3.10 (3H, s), 6.04 (2H, s), 8.28 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 24.2 (CH3), 67.6 (CH2), 117.6 (CH), 136.6 (C), 137.5 (C), 164.7 (C), 166.3 (C).
(6-Allyl-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate
To a stirred mixture of 2-allyl-6-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.16 g, 0.85 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (2 mL). The reaction mixture was then stirred at room temperature for 18 h, before evaporating to dryness to afford crude 2-allyl-6-(hydroxymethyl)pyrrolo[3,4- /]isoindolc-L3,5,7(2H,6H)-tctraonc, which was used directly in the next step. The resultant crude solid was taken up in 1,2 -dichloroethane (25 mL) and was added urea (1.5 mg, 0.03 mmol), 70% nitric acid (0.07 mL, 1.11 mmol) and acetic anhydride (0.20 mL, 2.12 mmol), then heated under reflux for 4 h. After cooling to room temperature, the reaction mixture was diluted with dichloromethane (20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded Compound 3 as a colourless solid (44.0 mg, 0.13 mmol, 32% over two steps). 1H NMR (400 MHz, CDC13) 5 4.37 (2H, dt, J= 5.9 and 1.4 Hz), 5.25-5.33 (2H, m), 5.85-5.95 (1H, m), 6.09 (2H, s), 8.39 (2H, s); 13C NMR (100 MHz, CDCI3) 5 41.0 (CH2), 66.6 (CH2), 119.2 (CH), 119.5 (CH2), 130.7 (CH), 136.6 (C), 138.1 (C), 164.2 (C), 165.4 (C).
(l,3,5,7-Tetraoxo-6-phenyl-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate (Compound 5)
A stirred mixture of 2-(hydroxymethyl)-6-phenylpyrrolo[3,4-f|isoindole-l, 3, 5, 7(2H,6H)- tetraone (0.20 g, 0.62 mmol), urea (2.0 mg, 0.03 mmol), 70% nitric acid (0.10 mL, 1.58 mmol) and acetic anhydride (0.29 mL, 3.07 mmol) in 1,2 -dichloroethane (40 mL) was heated under reflux for 18 h. After cooling to room temperature, the solids were collected by filtration, washed with CH2C12 (20 mL) and water (20 mL), then dried in vacuo to afford Compound 5 as a pale-yellow solid (0.11 g, 0.29 mmol, 48%). 1H NMR (400 MHz, d6-DMSO) δ 6.06 (2H,
s), 7.47-7.59 (5H, m), 8.39 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 67.6 (CH2), 118.1 (CH), 127.2 (CH), 128.4 (CH), 128.9 (CH), 131.5 (C), 136.8 (C), 137.3 (C), 164.7 (C), 165.3 (C).
(l,3,5,7-Tetraoxo-6-(pyridin-2-yl)-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)methyl nitrate (Compound 6)
A stirred mixture of 2-(hydroxymethyl)-6-(pyridin-2-yl)pyrrolo[3,4-f|isoindole- 1,3,5,7(2H,6H)-tetraone (0.25 g, 0.77 mmol), urea (1.2 mg, 0.02 mmol), 70% nitric acid (0.15 mL, 1.93 mmol) and acetic anhydride (0.37 mL, 3.87 mmol) in 1,2-dichloroethane (20 mL) was heated under reflux for 3 h. Additional 70% nitric acid (0.15 mL, 1.93 mmol) and acetic anhydride (0.37 mL, 3.87 mmol) was added, and the reaction mixture was then heated under reflux for a further 2 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo and water (20 mL) was added. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford Compound 6 as a paleyellow solid (0.15 g, 0.40 mmol, 53%). 1H NMR (500 MHz, d6-DMSO) δ 6.06 (2H, s), 7.57 (1H, ddd, 7 = 7.5, 4.6 and 0.8 Hz), 7.61 (1H, d, 7 = 7.9 Hz), 8.09 (lH, td, 7 = 7.7 and 1.9 Hz), 8.42 (2H, s), 8.68 (1H, dd, 7 = 4.8 and 1.1 Hz); 13C NMR (125 MHz, d6-DMSO) δ 67.6 (CH2), 118.5 (CH), 122.9 (CH), 124.5 (CH), 137.0 (C), 137.1 (C), 138.9 (CH), 145.5 (C), 149.5 (CH), 164.7 (C), 164.8 (C).
2-(Acetoxymethyl)-6-(6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (Compound 7)
A stirred mixture of 2-(acetoxymethyl)-6-(6-(hydroxymethyl)-l, 3,5, 7-tetraoxo-3, 5,6,7 - tetrahydropyrrolo[3,4-f|isoindol-2(1H)-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (0.38 g, 0.67 mmol), urea (2.3 mg, 0.04 mmol), 70% nitric acid (0.11 mL, 1.74 mmol) and acetic
anhydride (0.32 mL, 3.39 mmol) in 1,2-dichloroethane (25 mL) was heated under reflux for 3 h. After cooling to room temperature, the reaction mixture was diluted with dichloromethane (30 mL) and washed with water (30 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded Compound 7 as pale-yellow solid (0.24 g, 0.39 mmol, 65%). 1H NMR (400 MHz, CDC13) 5 1.88 (3H, s), 2.04 (3H, s), 2.07 (3H, s), 2.08 (3H, s), 3.88 (1H, dt, J = 9.9 and 3.6 Hz), 4.21-4.22 (2H, m), 5.25-5.38 (2H, m), 5.47 (1H, d, J = 9.4 Hz), 5.96 (1H, t, J = 9.3 Hz), 6.09 (2H, s), 8.43 (2H, s). 13C NMR (100 MHz, CDCI3) 5 20.5 (CH3), 20.7 (CH3), 20.8 (CH3), 61.8 (CH2), 66.6 (CH2), 67.9 (CH), 68.5 (CH), 73.4 (CH), 75.0 (CH), 78.4 (CH), 120.2 (CH), 137.0 (C), 163.9 (C), 169.5 (C), 169.6 (C), 170.2 (C), 170.7 (C).
(6-Acetyl-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate Compound 9
To a stirred mixture of crude 2-acetyl-6-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4- f]isoindole-1 ,3,5,7(2H,6H)-tctraonc (0.50 g) in dichloromethane (12 mL) was added trifluoroacetic acid (3 mL). The reaction mixture was then stirred at room temperature for 18 h, before evaporating to dryness to afford crude 2-acetyl-6-(hydroxymethyl)pyrrolo[3,4- f]isoindole-1 ,3,5,7(2H,6H)-tctraonc, which was used directly in the next step. The resultant crude solid was taken up in 1,2 -dichloroethane (15 mL) and was added urea (1.6 mg, 0.03 mmol), 70% nitric acid (0.20 mL, 2.60 mmol) and acetic anhydride (0.49 mL, 5.20 mmol) in 1,2-dichloroethane (15 mL), then heated under reflux for 2 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 7:3) afforded Compound 9 as a colourless solid (0.09 g, 0.26 mmol, 20% over two steps). 1H NMR (400 MHz, d6-DMSO) δ 2.58 (3H, s), 6.04 (CH2), 8.40 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 26.5 (CH3), 67.6 (CH2), 118.8 (CH), 136.5 (C), 137.4 (C), 163.9 (C), 164.5 (C), 168.3 (C).
Ethyl 6-((nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindole-
A stirred mixture of ethyl 6-(hydroxymethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.30 g, 0.94 mmol), urea (1.4 mg, 0.02 mmol), 70% nitric acid (0.19 mL, 2.36 mmol) and acetic anhydride (0.46 mL, 4.71 mmol) in 1,2-dichloroethane (15 mL) was heated under reflux for 2 h. Additional 70% nitric acid (0.19 mL, 2.36 mmol) and acetic anhydride (0.46 mL, 4.71 mmol) was added, and the reaction mixture was then heated under reflux for a further 2 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo, then diluted with ethyl acetate (30 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford Compound 10 as a colourless solid (0.26 g, 0.72 mmol, 76%). 1H NMR (400 MHz, d6- DMSO) δ 1.34 (3H, t, J = 7.1 Hz), 4.41 (2H, q, J = 7.1 Hz), 6.04 (2H, s), 8.37 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 13.9 (CH3), 63.5 (CH2), 67.6 (CH2), 118.7 (CH), 136.6 (C), 137.2 (C), 147.6 (C), 162.2 (C), 164.5 (C).
3-(6-((Nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)propane-l,2-diyl dinitrate (Compound 12)
A stirred mixture of 2-(2,3-dihydroxypropyl)-6-(hydroxymethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.23 g, 0.72 mmol), urea (3.2 mg, 0.05 mmol), 70% nitric acid (0.42 mL, 5.39 mmol) and acetic anhydride (1.02 mL, 10.8 mmol) in 1,2-dichloroethane (20 mL) was heated under reflux for 2 h. Additional 70% nitric acid (0.21 mL, 2.70 mmol) and acetic anhydride (0.51 mL, 5.39 mmol) was added, and the reaction mixture was then heated under reflux for a further 2 h. After cooling to room temperature, the precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford Compound 12 as a colourless solid (0.23 g, 0.56 mmol, 78%). 1H NMR (400 MHz, d6-DMSO) δ 4.07- 4.09 (2H, m), 4.90 (1H, dd, J = 12.5 and 6.2 Hz), 4.98 (1H, dd, J = 12.7 and 3.0 Hz), 5.62 (1H,
brs), 6.04 (2H, s), 8.34 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 36.4 (CH2), 67.6 (CH2), 70.1 (CH2), 77.3 (CH), 118.0 (CH), 136.7 (C), 137.3 (C), 164.7 (C), 166.1 (C).
2-(6-((Nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)propane-l,3-diyl dinitrate (Compound 13)
A stirred mixture of 2-(l,3-dihydroxypropan-2-yl)-6-(hydroxymethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.30 g, 0.94 mmol), urea (8.4 mg, 0.14 mmol), 70% nitric acid (0.45 mL, 7.03 mmol) and acetic anhydride (1.33 mL, 14.1 mmol) in 1,2-dichloroethane (15 mL) was heated under reflux for 3 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo, then diluted with ethyl acetate (20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 7:3) afforded Compound 13 as a colourless foam (0.16 g, 0.35 mmol, 38%). 1H NMR (500 MHz, d6-DMSO) 5 4.82-4.89 (1H, m), 4.98-5.07 (4H, m), 6.05 (2H, s), 8.37 (2H, s); 13C NMR (125 MHz, d6- DMSO) δ 45.9 (CH), 67.6 (CH2), 69.3 (CH2), 118.3 (CH), 136.7 (C), 137.0 (C), 164.6 (C), 165.6 (C).
Methyl 3-(nitrooxy)-2-(6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)propanoate (Compound 14)
A stirred mixture of methyl 3-hydroxy-2-(6-(hydroxymethyl)-l, 3,5, 7-tetraoxo-3, 5,6,7 - tetrahydropyrrolo[3,4-f|isoindol-2(1H)-yl)propanoate (0.28 g, 0.80 mmol), urea (4.8 mg, 0.08 mmol), 70% nitric acid (0.26 mL, 4.02 mmol) and acetic anhydride (0.76 mL, 8.04 mmol) in 1,2-dichloroethane (10 mL) was heated under reflux for 2 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. Purification by flash column chromatography (CH2Cl2/MeOH, 99:1) afforded Compound 14 as a colourless foam (0.16 g, 0.36 mmol, 44%).
1H NMR (400 MHz, d6-DMSO) δ 3.72 (3H, s), 4.99 (1H, dd, J = 12.0 and 8.2 Hz), 5.15 (1H, dd, J = 11.8 and 4.4 Hz), 5.54 (1H, dd, J = 8.5 and 4.4 Hz), 6.06 (2H, s), 8.42 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 49.0 (CH), 53.2 (CH3), 67.6 (CH2), 69.2 (CH2), 118.7 (CH), 119.0 (CH), 136.4 (C), 136.5 (C), 137.3 (C), 137.3 (C), 164.5 (C), 164.9 (C), 164.9 (C), 165.0 (C), 166.2 (C).
(6-(2-Hydroxyethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)methyl nitrate (Compound 15)
To a stirred solution of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7 - tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (6 mL) was added dropwise ethanolamine (17.0 mg, 0.28 mmol) in THF (2 mL). The reaction mixture was then stirred at room temperature for 1 h before being concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:4) afforded Compound 15 as a colourless solid (44 mg, 0.13 mmol, 48%). 1H NMR (400 MHz, d6-DMSO) δ 3.60-3.64 (2H, m), 3.69-3.72 (2H, m), 4.87 (1H, t, J = 6.0 Hz), 6.04 (2H, s), 8.29 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 41.0 (CH2), 57.8 (CH2), 67.6 (CH2), 117.7 (CH), 136.6 (C), 137.4 (C), 164.7 (C), 166.2 (C).
(6-(2-Methoxyethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)methyl nitrate (Compound 16)
To a stirred solution of 2-(2-methoxyethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.28 g, 1.02 mmol) in DMF (7.5 mL) was added paraformaldehyde (61.3 mg, 2.04 mmol), and the reaction mixture heated at 80 °C for 18 h, before evaporating to dryness to afford crude 2- (hydroxymethyl)-6-(2-methoxyethyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)-tetraone, which
was used directly in the next step. The resultant crude solid was taken up in 1,2 -dichloroethane (10 mL) and was added urea (0.8 mg, 0.01 mmol), 70% nitric acid (0.10 mL, 1.31 mmol) and acetic anhydride (0.25 mL, 2.63 mmol) in 1,2-dichloroethane (10 mL), then heated under reflux for 2 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo, diluted with ethyl acetate (20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford Compound 16 as a yellow solid (0.12 g, 0.34 mmol, 33% over two step). 1H NMR (400 MHz, d6-DMSO) δ 3.24 (3H, s), 3.57 (2H, t, J = 5.6 Hz), 3.81 (2H, t, J = 5.6 Hz), 6.04 (2H, s), 8.30 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 37.5 (CH2), 57.8 (CH3), 67.6 (CH2), 68.4 (CH2), 117.9 (CH), 136.8 (C), 137.2 (C), 165.8 (C), 166.0 (C).
6-(2-(Methylthio)ethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)methyl nitrate (Compound 17)
A mixture of ethyl 6-((nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- |isoindole-2(1H)-carboxylate (0.1 g, 0.275 mmol) and 2-(methylthio)ethylamine (27.6 mg, 0.303 mmol) in tetrahydrofuran (5 mL) was stirred at 50 °C for 18 h. The reaction mixture was concentrated in vacuo then diluted with ethyl acetate (20 mL) and washed with water (30 mL). The aqueous layer was repeatedly extracted with ethyl acetate (3 x 20 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 7:3) afforded Compound 17 as a pale yellow solid (36 mg, 0.099 mmol, 36%). 1H NMR (400 MHz, d6- DMSO) δ 2.10 (3H, s), 2.78 (2H, t, J = 6.9 Hz), 3.85 (2H, t, J = 6.9 Hz), 6.04 (2H, s), 8.32 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 14.3 (CH3), 31.0 (CH2), 36.7 (CH2), 67.6 (CH2), 118.0 (CH), 136.9 (C), 137.1 (C), 164.7 (C), 166.0 (C).
(6-(2-(Methylsulfinyl)ethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol- 2(lH)-yl)methyl nitrate (Compound 18)
A stirred mixture of 2-(hydroxymethyl)-6-(2-(methylthio)ethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.40 g, 1.25 mmol), urea (1.9 mg, 0.03 mmol), 70% nitric acid (0.25 mL, 3.12 mmol) and acetic anhydride (0.59 mL, 6.24 mmol) in 1,2-dichloroethane (15 mL) was heated under reflux for 2 h. Additional 70% nitric acid (0.25 mL, 3.12 mmol) and acetic anhydride (0.59 mL, 6.24 mmol) was added, and the reaction mixture was then heated under reflux for a further 2 h. After cooling to room temperature, the precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford Compound 18 as a pale-yellow solid (0.16 g, 0.42 mmol, 34%). 1H NMR (400 MHz, d6-DMSO) δ 2.59 (3H, s), 2.96-3.02 (1H, m), 3.13-3.20 (1H, m), 3.99-4.09 (2H, m), 6.04 (2H, s), 8.31 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 32.4 (CH2), 38.1 (CH2), 51.0 (CH3), 67.6 (CH2), 117.9 (CH), 136.7 (C), 137.3 (C), 164.7 (C), 165.8 (C).
(6-(2-(Methylsulfonyl)ethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-
A stirred mixture of 2-(hydroxymethyl)-6-(2-(methylsulfonyl)ethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.70 g, 1.99 mmol), urea (3.0 mg, 0.05 mmol), 70% nitric acid (0.39 mL, 4.97 mmol) and acetic anhydride (0.94 mL, 9.93 mmol) in 1,2-dichloroethane (20 mL) was heated under reflux for 3 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. Purification by flash column chromatography (CH2Cl2/MeOH, 49:1) afforded Compound 19 as a colourless solid (0.23 g, 0.58 mmol, 29%). 1H NMR (400 MHz, d6-DMSO) δ 3.08 (3H, s), 3.53 (2H, t, J = 6.8 Hz), 4.08 (2H, t, J = 6.8 Hz), 6.04 (2H, s), 8.33 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 31.7 (CH2), 40.4 (CH3), 50.5 (CH2), 67.6 (CH2), 118.0 (CH), 136.9 (C), 167.2 (C), 164.7 (C), 165.7 (C).
(6-(2-(Dimethylamino)ethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-
To a stirred solution of 2-(2-(dimethylamino)ethyl)-6-((2- (trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole-1,3,5,7(27/,67/)-tetraone (0.30 g, 0.72 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (2.5 mL). The reaction mixture was then stirred at room temperature for 18 h, before evaporating to dryness to afford crude 2-(2-(dimethylamino)ethyl)-6-(hydroxymethyl)pyrrolo[3,4-f|isoindole-1,3,5,7(2H,6H)- tetraone, which was used directly in the next step. The resultant crude residue was taken up in 1,2-dichloroethane (40 mL) and was added urea (2.2 mg, 0.033 mmol), 70% nitric acid (0.12 mL, 1.90 mmol) and acetic anhydride (0.34 mL, 3.60 mmol), then heated under reflux for 18 h. After cooling to room temperature, the solids were collected by filtration and washed with dichloromethane (20 mL). Purification by RP-HPLC afforded Compound 20 as its nitric acid salt (colourless solid; 53.0 mg, 0.12 mmol, 17% over two steps). 1H NMR (400 MHz, d6- DMSO ) 5 2.88 (3H, s), 2.89 (3H, s), 3.40-3.44 (2H, m), 4.01 (2H, t, J = 5.7 Hz), 6.05 (2H, s), 8.36 (2H, s), 9.36 (1H, brs); 13C NMR (100 MHz, d6-DMSO) δ 33.4 (CH2), 42.3 (CH3), 54.4 (CH2), 67.6 (CH2), 117.9 (CH), 136.8 (C), 137.4 (C), 164.7 (C), 166.2 (C).
(6-Benzyl-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate (Compound 21)
A stirred mixture of 2-benzyl-6-(hydroxymethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(27/,67/)- tetraone (0.25 g, 0.74 mmol), urea (2.3 mg, 0.04 mmol), 70% nitric acid (0.12 mL, 1.90 mmol) and acetic anhydride (0.35 mL, 3.71 mmol) in 1,2-dichloroethane (40 mL) was heated under reflux for 18 h. After cooling to room temperature, the solids were collected by filtration, washed with CH2C12 (20 mL) and water (20 mL), then dried in vacuo to afford Compound 21 as a colourless solid (0.13 g, 0.34 mmol, 46%). 1H NMR (400 MHz, d6-DMSO) δ 4.83 (2H, s),
6.04 (2H, s), 7.27-7.37 (5H, m), 8.32 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 41.5 (CH2), 67.6 (CH2), 118.0 (CH), 127.5 (CH), 127.6 (CH), 128.6 (CH), 136.1 (C), 136.7 (C), 137.3 (C), 164.7 (C), 166.0 (C).
(l,3,5,7-Tetraoxo-6-(pyridin-2-ylmethyl)-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)methyl nitrate (Compound 22)
A stirred mixture of 2-(hydroxymethyl)-6-(pyridin-2-ylmethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.20 g, 0.59 mmol), urea (0.9 mg, 0.01 mmol), 70% nitric acid (0.12 mL, 1.48 mmol) and acetic anhydride (0.28 mL, 2.96 mmol) in 1,2-dichloroethane (5 mL) was heated under reflux for 2 h. After cooling to room temperature, the solids were collected by filtration, washed with (20 mL), then dried in vacuo to afford Compound 22 as a colourless solid (0.16 g, 0.42 mmol, 71%). 1H NMR (400 MHz, d6-DMSO) δ 5.03 (2H, s), 6.06 (2H, s), 7.55 (1H, t, J = 5.7 Hz), 7.73 (1H, d, J = 8.7 Hz), 8.08 (1H, t, J = 7.5 Hz), 8.32 (2H, s), 8.61 (1H, d, J = 4.6 Hz); 13C NMR (100 MHz, d6-DMSO) δ 41.4 (CH2), 67.6 (CH2), 117.9 (CH), 132.2 (CH), 133.9 (CH), 137.0 (C), 137.3 (C), 146.6 (CH), 153.2 (C), 165.8 (C), 166.0 (C).
2-(6-((Nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)acetic add (Compound 24)
A stirred mixture of 2-(6-(hydroxymethyl)-l, 3,5,7 -tetraoxo-3, 5,6,7 -tetrahydropyrrole [3, 4- |isoindol-2(1H)-yl)acetic acid (0.15 g, 0.49 mmol), urea (0.7 mg, 0.01 mmol), 70% nitric acid (0.10 mL, 1.23 mmol) and acetic anhydride (0.23 mL, 2.47 mmol) in 1,2-dichloroethane (10 mL) was heated under reflux for 5 h. After cooling to room temperature, the precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford Compound 24 as a colourless solid (0.08 g, 0.23 mmol, 47%). 1H NMR (500 MHz, d6-DMSO)
5 4.40 (2H, s), 6.05 (2H, s), 8.38 (2H, s), 13.39 (1H, brs); 13C NMR (125 MHz, d6-DMSO) δ
39.2 (CH2), 67.6 (CH2), 118.3 (CH), 136.9 (C), 137.1 (C), 164.7 (C), 165.5 (C), 168.5 (C).
Methyl 2-(6-((nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-
A stirred mixture of methyl 2-(6-(hydroxymethyl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f|isoindol-2(1H)-yl)acetate (0.11 g, 0.35 mmol), urea (0.5 mg, 0.01 mmol), 70% nitric acid (0.07 mL, 0.86 mmol) and acetic anhydride (0.16 mL, 1.73 mmol) in 1,2-dichloroethane (10 mL) was heated under reflux for 2 h. Aftercooling to room temperature, the reaction mixture was diluted with dichloromethane (20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford Compound 25 as a colourless solid (0.12 g, 0.32 mmol, 93%). 1H NMR (500 MHz, d6-DMSO) δ 3.71 (3H, s), 4.53 (2H, s), 6.05 (2H, s), 8.39 (2H, s); 13C NMR (125 MHz, d6-DMSO) δ 39.2 (CH2), 52.6 (CH3), 67.6 (CH2), 118.4 (CH), 136.8 (C), 137.2 (C), 164.6 (C), 165.3 (C), 167.7 (C).
(6-(2-(Dimethylamino)-2-oxoethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- f]isoindol-2(lH)-yl)methyl nitrate (Compound 26)
A stirred mixture of 2-(6-(hydroxymethyl)-l, 3,5,7 -tetraoxo-3, 5,6,7 -tetrahydropyrrolo [3, 4- f|isoindol-2(1H)-yl)-N,N-dimethylacetamide (0.25 g, 0.75 mmol), urea (1.1 mg, 0.02 mmol), 70% nitric acid (0.15 mL, 1.89 mmol) and acetic anhydride (0.36 mL, 3.77 mmol) in 1,2- dichloroethane (15 mL) was heated under reflux for 3 h. After cooling to room temperature, the precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford Compound 26 as a colourless solid (0.15 g, 0.40 mmol, 53%). 1H NMR (500 MHz, d6-DMSO) δ 2.85 (3H, s), 3.09 (3H, s), 4.58 (2H, s), 6.05 (2H, s), 8.36 (2H, s); 13C NMR
(125 MHz, d6-DMSO) δ 35.3 (CH3), 35.8 (CH3), 67.6 (CH2), 118.2 (CH), 137.1 (C), 164.7 (C), 164.9 (C), 165.8 (C).
(6-(2, 5, 8,11, 14-Pentaoxahexadecan-16-yl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate (Compound 27)
A stirred mixture of 2-(2,5,8,l l,14-pentaoxahexadecan-16-yl)-6-(hydroxymethyl)pyrrolo[3,4- |isoindole-l,3,5,7(2H,6H)-tetraone (0.35 g, 0.73 mmol), urea (1.1 mg, 0.02 mmol), 70% nitric acid (0.14 mL, 1.82 mmol) and acetic anhydride (0.34 mL, 3.64 mmol) in 1,2-dichloroethane (20 mL) was heated under reflux for 3 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. Purification by flash column chromatography (CH2Cl2/MeOH, 49:1) afforded Compound 27 as a yellow oil (0.31 g, 0.59 mmol, 81%). 1H NMR (400 MHz, d6-DMSO) δ 3.23 (3H, s), 3.40-3.53 (16H, m), 3.66 (2H, t, J = 5.8 Hz), 3.81 (2H, t, J = 5.8 Hz), 6.04 (2H, s), 8.30 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 37.7 (CH2), 58.0 (CH3), 66.8 (CH2), 67.6 (CH2), 69.5 (CH2), 69.6 (CH2), 69.7 (CH2), 71.2 (CH2), 117.9 (CH), 136.7 (C), 137.2 (C), 164.7 (C), 166.0 (C).
A stirred solution of 2-(2-hydroxyethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.20 g, 0.77 mmol), urea (2.3 mg, 0.04 mmol), 70% nitric acid (0.12 mL, 1.90 mmol) and acetic anhydride (0.36 mL, 3.82 mmol) in 1,2-dichloroethane (30 mL) was heated under reflux for 18 h. After cooling to room temperature, the reaction mixture was diluted with dichloromethane
(20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (CH2Ch/MeOH, 9:1) afforded Compound 28 as a colourless solid (68.0 mg, 0.22 mmol, 29%). 1H NMR (400 MHz, d6-DMSO) δ 4.00 (2H, t, J = 5.1 Hz), 4.73 (2H, t, J = 5.1 Hz), 8.18 (2H, s), 11.84 (1H, brs); 13C NMR (400 MHz, d6-DMSO) δ 35.3 (CH2), 70.7 (CH2), 117.4 (CH), 136.8 (C), 138.1 (C), 166.1 (C), 167.5 (C).
(6-Ethyl-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)methyl nitrate (Compound 29)
To a stirred mixture of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7 - tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (10 mL) was added dropwise ethylamine (0.14 mL, 2 M in THF, 0.28 mmol). The reaction mixture was then stirred at room temperature for 18 h before being concentrated in vacuo to about ~3 mL in volume, and the residue triturated with Et2O (30 mL). The resulting solids were collected by filtration, washed with Et2O and dried in vacuo to afford Compound 29 as a beige solid (71.0 mg, 0.22 mmol, 81%). 1H NMR (400 MHz, d6-DMSO) δ 1.21 (3H, t, J = 7.2 Hz), 3.67 (2H, q, J = 7.2 Hz), 6.04 (2H, s), 8.28 (2H, s).
(6-(l,3-Dihydroxypropan-2-yl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-
A mixture of ethyl 6-((nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- |isoindole-2(1H)-carboxylate (0.1 g, 0.275 mmol) and serinol (2-amino-l,3-propanediol) (27.6 mg, 0.303 mmol) in tetrahydrofuran (3 mL) was stirred at room temperature for 5.5 h. The reaction mixture was concentrated in vacuo then diluted with ethyl acetate (20 mL) and
washed with water (30 mL). The aqueous layer was repeatedly extracted with ethyl acetate (3 x 20 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (CH2Cl2/acetone, 8:2) afforded Compound 30 as a colourless solid (39 mg, 0.107 mmol, 39%). 1H NMR (400 MHz, d6-DMSO) δ 3.68 (2H, m), 3.83 (2H, t, J = 10.6 Hz), 4.29 (1H, m), 4.93 (2H, brs), 6.05 (2H, s), 8.29 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 57.4 (CH), 58.0 (CH2), 67.6 (CH2), 117.7 (CH), 136.7 (C), 137.2 (C), 164.8 (C), 166.6 (C).
(6-(2,3-Dihydroxypropyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol- 2(lH)-yl)methyl nitrate (Compound 31)
A mixture of ethyl 6-((nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- |isoindole-2(1H)-carboxylate (0.1 g, 0.275 mmol) and 3-amino-l,2-propanediol (0.023 mL, 0.302 mmol) in tetrahydrofuran (3 mL) was stirred at room temperature for 1.5 h. The reaction mixture was concentrated in vacuo then diluted with ethyl acetate (20 mL) and washed with water (30 mL). The aqueous layer was repeatedly extracted with ethyl acetate (3 x 20 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 3:7) afforded Compound 31 as a colourless solid (27 mg, 0.074 mmol, 27%). 1H NMR (400 MHz, d6- DMSO) δ 3.34-3.45 (2H, m), 3.64 (2H, d, J = 6.3 Hz), 3.81-3.87 (1H, m), 4.70 (1H, t, J = 5.3 Hz), 4.98 (1H, d, J = 5.3 Hz), 6.04 (2H, s), 8.29 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 42.4 (CH2), 64.1 (CH2), 67.6 (CH2), 68.3 (CH), 117.7 (CH), 136.6 (C), 137.4 (C), 164.8 (C), 166.3 (C).
(6-(2-(2-(2-Methoxyethoxy)ethoxy)ethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- /|isoindol-2( 1H)-yl)methyl nitrate (Compound 32)
To a stirred solution of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7 - tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (6 mL) was added dropwise 2-(2-(2-methoxyethoxy)ethoxy)ethanamine (45.0 mg, 0.28 mmol) in THF (2 mL). The reaction mixture was stirred at room temperature for 18 h before being diluted with EtOAc (15 mL) and washed with H2O (10 mL). The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:4) afforded Compound 32 as a beige solid (72.0 mg, 0.16 mmol, 60%). 1H NMR (400 MHz, d6-DMSO) δ 3.18 (3H, s), 3.33-3.35 (2H, m), 3.42-3.46 (4H, m), 3.51-3.53 (2H, m), 3.64-3.67 (2H, m), 3.79-3.82 (2H, m), 6.04 (2H, s), 8.30 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 37.7 (CH2), 58.0 (CH3), 66.8 (CH2), 67.6 (CH2), 69.47 (CH2), 69.53 (CH2), 69.6 (CH2), 71.2 (CH2), 117.9 (CH), 136.7 (C), 137.2 (C), 164.7 (C), 166.0 (C).
((6-(2-Amino-2-oxoethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-
To a solution of 2-aminoacetamide hydrochloride (33.5 mg, 0.303 mmol) in tetrahydrofuran (2 mL) was added triethylamine (0.042 mL, 0.303 mmol), and the mixture stirred at room temperature for 10 minutes. To this mixture was added ethyl 6-((nitrooxy)methyl)-l,3,5,7- tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.1 g, 0.275 mmol) in tetrahydrofuran (5 mL), and the mixture stirred at room temperature for a further 18 h. The reaction mixture was concentrated in vacuo then diluted with ethyl acetate (20 mL) and washed with water (30 mL). The aqueous layer was repeatedly extracted with ethyl acetate (3 x 20 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo. The resulting solids were washed with ether (3 x 10 mL) to afford the Compound 33 as a colourless solid (50 mg, 0.096 mmol, 52%). 1H NMR (400 MHz, d6- DMSO) δ 4.21 (2H, s), 6.05 (2H, s), 7.33 (1H, brs), 7.75 (1H, brs), 8.35 (2H, s); 13C NMR (100
MHz, d6-DMSO) δ 40.5 (CH2), 67.6 (CH2), 118.1 (CH), 136.9 (C), 137.3 (C), 164.7 (C), 165.8
(C), 167.6 (C).
(6-(2-Mercaptoethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)methyl nitrate (Compound 34)
A mixture of ethyl 6-((nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- |isoindole-2(1H)-carboxylate (0.1 g, 0.275 mmol) and 2-aminoethanethiol (23.4 mg, 0.303 mmol) in tetrahydrofuran (5 mL) was stirred at room temperature for 1.5 h. The reaction mixture was concentrated in vacuo then diluted with ethyl acetate (20 mL) and washed with water (30 mL). The aqueous layer was repeatedly extracted with ethyl acetate (3 x 20 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo. The resulting solids were washed with ether (3 x 10 mL) to afford Compound 34 as a colourless solid (65 mg, 0.097 mmol, 67%). 1H NMR (400 MHz, d6-DMSO) δ 2.77 (2H, t, J = 4.8 Hz), 3.78-3.81 (2H, m), 6.04 (2H, s), 8.31 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 21.9 (CH2), 41.0 (CH2), 67.6 (CH2), 117.9 (CH), 136.7 (C), 137.3 (C), 164.7 (C), 166.0 (C).
(l,3,5,7-Tetraoxo-6-(2-sulfamoylethyl)-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(1H)- yl)methyl nitrate (Compound 35)
To a stirred solution of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (6 mL) was added 2-aminoethanesulfonamide (35.0 mg, 0.28 mmol). The reaction mixture was then stirred at room temperature for 18 h before adding H2O (10 mL). The resulting precipitated solids were then collected by filtration, washed with H2O and dried in vacuo to afford Compound 35 as a beige solid (42 mg, 0.11 mmol, 38%). 1H NMR (400 MHz, d6-DMSO) δ 3.36-3.40 (2H,
m), 4.00-4.04 (2H, m), 6.04 (2H, s), 7.07 (2H, s), 8.31 (2H, s); 13C NMR (100 MHz, d6-DMSO)
5 33.1 (CH2), 51.4 (CH2), 67.6 (CH2), 117.8 (CH), 136.7 (C), 137.3 (C), 164.7 (C), 165.7 (C).
6-((l-Methyl-lH-tetrazol-5-yl)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- f]isoindol-2(lH)-yl)methyl nitrate (Compound 36)
To a stirred solution of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (6 mL) was added dropwise (l-methyl-1H-tetrazol-5-yl)methanamine (32.0 mg, 0.28 mmol) in THF (2 mL). The reaction mixture was then stirred at room temperature for 18 h before being concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:4) afforded Compound 36 as a beige solid (23.0 mg, 0.06 mmol, 22%). 1H NMR (400 MHz, d6-DMSO) δ 4.15 (3H, s), 5.23 (2H, s), 6.05 (2H, s), 8.37 (2H, s); 13C NMR (100 MHz, d6- DMSO) δ 30.9 (CH3), 33.9 (CH2), 67.6 (CH2), 118.3 (CH), 136.99 (C), 137.04 (C), 151.1 (C), 164.7 (C), 165.4 (C).
(6-((l-Ethyl-lH-tetrazol-5-yl)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- f]isoindol-2(lH)-yl)methyl nitrate (Compound 37)
To a stirred solution of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7 - tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (6 mL) was added dropwise (l-ethyl-1H-tetrazol-5-yl)methanamine (35.0 mg, 0.28 mmol) in THF (2 mL). The reaction mixture was then stirred at room temperature for 18 h before being concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:4) afforded Compound 37 as a beige solid (23.0 mg, 0.06 mmol, 22%). 1H NMR (400 MHz, d6-DMSO) 5 1.50 (3H, t, J = 7.3 Hz), 4.53 (2H, q, J = 7.3 Hz), 5.24 (2H, s), 6.05 (2H, s), 8.38 (2H, s).
(6-((l-Benzyl-lH-tetrazol-5-yl)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- f]isoindol-2(1H)-yl)methyl nitrate (Compound 38)
To a stirred solution of ethyl 6-((nitrooxy)methyl)-l, 3,5, 7-tetraoxo-3, 5,6,7- tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.10 g, 0.28 mmol) in THF (6 mL) was added dropwise (l-benzyl-1H-tetrazol-5-yl)methanamine (53.0 mg, 0.28 mmol) in THF (2 mL). The reaction mixture was then stirred at room temperature for 18 h before being concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:2) afforded Compound 38 as a beige solid (64.0 mg, 0.14 mmol, 50%). 1H NMR (400 MHz, d6-DMSO) δ 5.23 (2H, s), 5.78 (2H, s), 6.05 (2H, s), 7.20-7.34 (5H, m), 8.31 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 31.3 (CH2), 50.2 (CH2), 67.6 (CH2), 118.3 (CH), 127.4 (CH), 128.3 (CH), 128.8 (CH), 134.0 (C), 136.8 (C), 136.9 (C), 151.0 (C), 164.6 (C), 165.2 (C).
2-(6-((Nitrooxy)methyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)ethyl nitrate (Compound 39)
A stirred mixture of 2-(2-hydroxyethyl)-6-(hydroxymethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.41 g, 1.41 mmol), urea (8.4 mg, 0.14 mmol), 70% nitric acid (0.45 mL, 7.11 mmol) and acetic anhydride (1.40 mL, 14.8 mmol) in 1,2-dichloroethane (20 mL) was heated under reflux for 3 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo and the solids were washed with CH2C12 (20 mL) and water (20 mL), then dried in vacuo to afford Compound 39 as a colourless solid (0.23 g, 0.60 mmol, 43%). 1H NMR (400 MHz, d6-DMSO) δ 4.01 (2H, t, J = 5.0 Hz), 4.74 (2H, t, J = 5.0 Hz), 6.04 (2H, s), 8.33 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 35.4 (CH2), 67.6 (CH2), 70.7 (CH2), 118.0 (CH), 136.8 (C), 137.2 (C), 164.7 (C), 165.9 (C).
3-(6-(2-(Nitrooxy)ethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)propane-l,2-diyl dinitrate (Compound 40)
A stirred mixture of 2-(2,3-dihydroxypropyl)-6-(2-hydroxyethyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (100 mg, 0.299 mmol), urea (2.7 mg, 0.045 mmol), 70% nitric acid (0.14 mL, 2.24 mmol) and acetic anhydride (0.42 mL, 4.49 mmol) in 1,2 -dichloroethane (5 mL) was heated under reflux for 0.5 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo and ice water (30 mL) was added. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford Compound 40 as a colourless solid (130 mg, 0.277 mmol, 93%). 1H NMR (400 MHz, d6-DMSO) δ 4.01 (2H, t, J = 5.1 Hz), 4.07 (1H, d, J = 2.3 Hz), 4.08 (1H, d, J = 1.5 Hz), 4.74 (2H, t, J = 4.7 Hz), 4.89 (1H, dd, J = 12.6 and 6.3 Hz), 4.98 (1H, dd, J = 12.5 and 3.0 Hz), 5.60-5.65 (1H, m), 8.29 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 35.4 (CH2), 36.3 (CH2), 70.1 (CH2), 70.7 (CH2), 77.3 (CH), 117.5 (CH), 136.9 (C), 137.1 (C), 166.0 (C), 166.2 (C).
3-(6-(l-(Nitrooxy)propan-2-yl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-
A stirred mixture of 2-(2,3-dihydroxypropyl)-6-(l-hydroxypropan-2-yl)pyrrolo[3,4- |isoindole-l,3,5,7(2H,6H)-tetraone (40 mg, 0.115 mmol), urea (1.0 mg, 0.017 mmol), 70% nitric acid (0.05 mL, 0.861 mmol) and acetic anhydride (0.16 mL, 1.72 mmol) in 1,2- dichloroethane (5 mL) was heated under reflux for 0.5 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo and ice water (30 mL) was added. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded Compound 41as a colourless foam (29 mg, 0.059 mmol, 52%). 1H NMR (400 MHz, d6-
DMSO) δ 1.51 (3H, d, J = 7.1 Hz), 4.07-4.09 (2H, m), 4.61-4.65 (1H, m), 4.81 (1H, ddd, J = 11.4, 4.5 and 0.7 Hz), 4.87-4.93 (2H, m), 4.98 (1H, d, J = 12.7 and 3.1 Hz), 5.60-5.64 (1H, m), 8.27 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 14.3 (CH3), 36.4 (CH2), 44.3 (CH), 70.1 (CH2), 72.7 (CH2), 77.3 (CH), 117.6 (CH), 136.6 (C), 137.1 (C), 166.0 (C), 166.2 (C).
3-(6-(3-(Nitrooxy)butan-2-yl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol- 2(lH)-yl)propane-l,2-diyl dinitrate (Compound 42)
To a solution of pyromellitic dianhydride (1.00 g, 4.58 mmol) in DMF (50 mL) was added slowly 3-amino-2-butanol (409 mg, 4.58 mmol) in DMF (5 mL) and 3 -aminopropane- 1,2-diol (418 mg, 4.58 mmol) in DMF (5 mL). The reaction mixture was then heated at 100 °C for 18 h, before being diluted with water (100 mL). The precipitated solids were collected by filtration, washed with water (3 x 50 mL), then dried in vacuo. The resulting residue (90 mg) was taken up in 1,2-dichloroethane (5 mL) and to this was added urea (2.2 mg, 0.037 mmol), acetic anhydride (0.35 mL, 3.73 mmol) and 70% nitric acid (0.12 mL, 1.86 mmol), and the mixture heated at reflux for 2 h. Following cooling to room temperature, the reaction mixture was first concentrated in vacuo, then diluted with ethyl acetate (20 mL) and washed with water (20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 7:3) afforded Compound 42 as an inseparable 1:1 mixture of diastereomers (colourless foam, 42 mg, 0.084 mmol, 2% over two steps). 1H NMR (400 MHz, d6-DMSO) δ 1.33 (3H, d, J = 6.5 Hz), 1.55 (3H, d, J = 7.3 Hz), 4.03-4.11 (2H, m), 4.53 (1H, qd, J = 7.1 and 5.4 Hz), 4.88 (2H, ddd, J = 12.7, 6.4 and 2.2 Hz), 5.49 (1H, qd, J = 6.5 and 5.6 Hz), 5.59-5.65 (1H, m), 8.27 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 13.1 (CH3), 14.4 (CH3), 36.3 (CH2), 48.9 (CH), 70.1 (CH2), 77.3 (CH), 80.8 (CH), 117.58 (CH), 136.6 (C), 137.13 (C), 166.0 (C), 166.23 (C). Other diastereomer: 1H NMR (400 MHz, d6-DMSO) δ 1.43 (3H, d, J = 6.4 Hz), 1.50 (3H, d, J = 7.2 Hz), 4.03-4.11 (2H, m), 4.44 (1H, dq, J = 9.1 and 7.2 Hz), 4.98 (2H, dt, J = 12.6 and 3.0 Hz), 5.59-5.65 (2H, m), 8.26 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 14.6 (CH3), 16.1 (CH3),
36.4 (CH2), 48.8 (CH), 70.1 (CH2), 77.3 (CH), 81.6 (CH), 117.6 (CH), 136.7 (C), 137.07 (C), 166.22 (C), 166.4 (C).
The following precursor or intermediate compounds referred to above were made as follows:
A mixture of 2-methylpyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.54 g, 2.35 mmol) and paraformaldehyde (0.11 g, 3.66 mmol) in DMF (15 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (2 x 20 mL), then dried in vacuo to afford the title compound as a colourless solid (0.41 g, 1.58 mmol, 67%). 1H NMR (400 MHz, d6-DMSO) δ 3.10 (3H, s), 5.01 (2H, d, J = 7.1 Hz), 6.52 (1H, t, J = 7.1 Hz), 8.24 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 24.2 (CH3), 60.6 (CH2), 117.7 (CH), 136.7 (C), 137.5 (C), 165.8 (C), 166.4 (C).
To a stirred solution of pyromellitic imide anhydride (5.00 g, 23.0 mmol) in acetone (150 mL) at 0 °C was added methylamine (7.20 mL, 33 wt. % in EtOH, 58.4 mmol) dropwise. The reaction mixture was stirred at room temperature for 30 min and concentrated in vacuo. Water (25 mL) was then added and the insoluble solids filtered off. The filtrate was then acidified to pH 1 with 2 M aq. hydrochloric acid solution and the mixture stirred at room temperature for 18 h. The precipitated solids were collected by filtration, washed with water (20 mL) then dried in vacuo to afford the title compound as a colourless solid (1.53 g, 6.65 mmol, 29%). 1H NMR (400 MHz, d6-DMSO) δ 3.09 (3H, s), 8.13 (2H, s), 11.81 (1H, brs).
2-Allyl-6-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)- tetraone
To a stirred solution of 2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.37 g, 1.07 mmol) in DMF (10 mL) at room temperature was added sodium hydride (51.0 mg, 60% dispersion in mineral oil, 1.28 mmol), and the reaction mixture was stirred for 30 min. Allyl bromide (0.11 mL, 1.27 mmol) was then added dropwise and the reaction mixture stirred at room temperature for a further 18 h, then quenched with water (20 mL). The resulting solids were filtered, washed with water (10 mL), then dried in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded the title compound as a colourless solid (0.33 g, 0.85 mmol, 80%). 1H NMR (400 MHz, CDCL) 6 -0.00 (9H, s), 0.94-0.98 (2H, m), 3.65-3.69 (2H, m), 4.36 (2H, dt, J = 5.9 and 1.4 Hz), 5.16 (2H, s), 5.24-5.33 (2H, m), 5.85-5.94 (1H, m), 8.35 (2H, s); 13C NMR (400 MHz, CDCI3) 6 -1.29 (CH3), 18.1 (CH2), 40.9 (CH2), 67.4 (CH2), 67.8 (CH2), 119.0 (CH), 130.8 (CH2). 137.2 (C), 137.7 (C), 165.8 (C), 166.0 (C).
To a stirred solution of pyromellitic diimide (2.00 g, 9.25 mmol) in DMF (200 mL) was added sodium hydride (0.24 g, 60% dispersion in mineral oil, 10.2 mmol). The reaction mixture was stirred at room temperature for 30 min before 2-(triemethylsilyl)ethoxymethyl chloride (1.80 mL, 10.2 mmol) was added dropwise. After a further 1 h, the reaction mixture was quenched with water (200 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were then washed with brine (3 x 200 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 3:1) afforded the title compound as a colourless solid (0.64 g, 1.85 mmol, 20%). 1H NMR (400
MHz, d6-DMSO) δ -0.03 (9H, s), 0.87 (2H, dd, J = 8.9 and 7.8 Hz), 3.61 (2H, dd, J = 8.9 and 7.9 Hz), 5.01 (2H, s), 8.35 (2H, s), 11.86 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ -1.4 (CH3), 17.3 (CH2), 66.3 (CH2), 66.9 (CH2), 117.7 (CH), 136.6 (C), 138.2 (C), 166.2 (C), 167.5 (C); ESI-MS: m/z calcd for C16H18N2O5Si: 346.0985; found [M+Na]+: 369.0867.
A stirred solution of 2-phenylpyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.50 g, 1.71 mmol) and paraformaldehyde (77.0 mg, 2.56 mmol) in DMF (15 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (40 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (2 x 20 mL), then dried in vacuo to afford the title compound as a pale-yellow solid (0.25 g, 0.78 mmol, 45%). 1H NMR (400 MHz, d6-DMSO) δ 5.04 (2H, d, J = 7.1 Hz), 6.55 (1H, t, J = 7.1 Hz), 7.46-7.59 (5H, m), 8.35 (2H, s); 13C NMR (400 MHz, d6-DMSO) δ 60.7 (CH2), 117.9 (CH), 127.3 (CH), 128.4 (CH), 129.0 (CH), 131.5 (C), 136.9 (C), 137.2 (C), 165.4 (C), 165.8 (C).
To a stirred solution of pyromellitic imide anhydride (1.00 g, 4.61 mmol) in DMF (15 mL) at 0 °C was added aniline (0.42 mL, 4.60 mmol) dropwise, then the reaction mixture was heated at 100 °C for 18 h. After cooling to room temperature, the insoluble by-products were filtered off, and water (40 mL) was added to the filtrate. The precipitated solids were collected by filtration, washed with water (20 mL), then dried in vacuo to afford the title compound as a pale-yellow solid (0.70 g, 2.40 mmol, 52%). 1H NMR (400 MHz, d6-DMSO) δ 7.45-7.58 (5H, m), 8.24 (2H, s), 11.88 (1H, brs); 13C NMR (400 MHz, d6-DMSO) δ 117.5 (CH), 127.3 (CH), 128.4 (CH), 128.9 (CH), 131.5 (C), 136.8 (C), 138.1 (C), 165.5 (C), 167.5 (C).
2-(Hydroxymethyl)-6-(pyridin-2-yl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)-tetraone
A stirred mixture of 2-(pyridin-2-yl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.40 g, 1.36 mmol) and paraformaldehyde (81.9 mg, 2.73 mmol) in DMF (5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a pale-yellow solid (0.42 g, 1.30 mmol, 95%). 1H NMR (400 MHz, d6-DMSO) δ 5.04 (2H, d, J = 7.1 Hz), 6.56 (1H, t, J = 7.1 Hz), 7.57 (1H, ddd, J = 7.5, 4.9 and 1.0 Hz), 7.60 (1H, d, J = 7.9 Hz), 8.08 (1H, td, J = 11.6 and 1.9 Hz), 8.37 (2H, s), 8.68 (1H, ddd, J = 4.8, 1.9 and 0.7 Hz); 13C NMR (100 MHz, d6-DMSO) δ 60.7 (CH2), 118.3 (CH), 122.9 (CH), 124.4 (CH), 137.0 (C), 137.2 (C), 138.9 (CH), 145.5 (C), 149.5 (CH), 164.8 (C), 165.7 (C).
A stirred mixture of pyromellitic imide anhydride (0.50 g, 2.30 mmol) and pyridine-2-amine (0.26 g, 2.76 mmol) in DMF (5 mL) was heated at 100 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), and dried in vacuo. Purification by flash column chromatography (CH2Cl2/acetone, 9:1) afforded the title compound as a pale-yellow solid (0.48 g, 1.64 mmol, 71%). 1H NMR (400 MHz, d6-DMSO) δ 7.56 (1H, ddd, J = 7.5, 4.9 and 1.1 Hz), 7.59 (1H, dt, J = 8.0 and 0.9 Hz), 8.07 (1H, td, J = 11.5 and 1.9 Hz), 8.27 (2H, s), 8.67 (1H, ddd, J = 4.8, 1.9 and 0.8 Hz), 11.90 (1H, brs); 13C NMR (100 MHz, d6-DMSO) δ
117.9 (CH), 122.9 (CH), 124.4 (CH), 136.6 (C), 138.3 (C), 138.9 (CH), 145.5 (C), 149.5 (CH),
164.9 (C), 167.5 (C).
2-(Acetoxymethyl)-6-(6-(hydroxymethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- f]isoindol-2(lH)-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
To a stirred solution of 2-(acetoxymethyl)-6-(l,3,5,7-tetraoxo-6-((2- (trimethylsilyl)ethoxy)methyl)-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindol-2(1H)-yl)tetrahydro- 2 H-pyran-3,4,5-triyl triacetate (0.45 g, 0.66 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (2 mL), and the reaction mixture stirred at room temperature for 18 h. The reaction was then diluted with dichloromethane (15 mL) and washed with sat. aq. sodium bicarbonate solution (2 x 10 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the title compound as a pale-yellow solid (0.38 g, 2.05 mmol, 99%). 1H NMR (400 MHz, CDC13) 6 1.89 (3H, s), 2.04 (3H, s), 2.07 (3H, s), 2.08 (3H, s), 3.23 (1H, t, J = 8.1 Hz), 3.88 (1H, dt, J = 9.9 and 3.6 Hz), 4.21-4.22 (2H, m), 5.25-5.38 (4H, m), 5.48 (1H, d, J = 9.4 Hz), 5.98 (1H, t, J = 9.3 Hz), 8.38 (2H, s); 13C NMR (400 MHz, CDCI3) 6 20.5 (CH3), 20.7 (CH3), 20.8 (CH3), 61.8 (CH2), 62.3 (CH2), 67.9 (CH), 68.5 (CH), 73.4 (CH), 75.0 (CH), 78.4 (CH), 119.7 (CH), 137.6 (C), 165.5 (C), 169.5 (C), 169.6 (C), 170.2 (C), 170.8 (C).
2-(Acetoxymethyl)-6-(l, 3,5, 7-tetraoxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3, 5,6,7- tetrahydropyrrolo[3,4-f]isoindol-2(1H)-yl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
To a stirred solution of 2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.60 g, 1.73 mmol) in DMF (10 mL) at room temperature was added sodium hydride (76.0 mg, 60% dispersion in mineral oil, 1.90 mmol), and the reaction mixture stirred for 30 min. 2-(Acetoxymethyl)-6-bromotetrahydro-1H-pyran-3,4,5-triyl triacetate (0.79 g, 1.92 mmol) in DMF (5 mL) was then added dropwise and the reaction mixture stirred at room temperature for a further 18 h, then quenched with water (30 mL). The resulting solids
were filtered, washed with water (10 mL) and dried in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded the title compound as a pale-yellow solid (0.46 g, 0.68 mmol, 39%). 1H NMR (400 MHz, CDC13) 6 0.00 (9H, s), 0.94-0.98 (2H, m), 1.89 (3H, s), 2.04 (3H, s), 2.07 (3H, s), 2.08 (3H, s), 3.64-3.68 (2H, m), 3.88 (1H, dt, J = 9.9 and 3.6 Hz), 4.22 (2H, d, J = 3.6 Hz), 5.16 (2H, s), 5.25-5.38 (2H, m), 5.47 (1H, d, J = 9.4 Hz), 5.98 (1H, t, J = 9.3 Hz), 8.38 (2H, s); 13C NMR (400 MHz, CDCI3) 6 -1.3 (CH3), 18.1 (CH2), 20.5 (CH3), 20.7 (CH3), 20.8 (CH3), 61.8 (CH2), 67.5 (CH2), 67.8 (CH2), 67.9 (CH), 68.5 (CH), 73.4 (CH), 74.9 (CH), 78.3 (CH), 119.6 (CH), 137.6 (C), 165.7 (C), 169.5 (C), 169.6 (C), 170.2 (C), 170.7 (C).
To a stirred solution of 2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.50 g, 1.44 mmol) in DMF (10 mL) was added sodium hydride (58.9 mg, 60% dispersion in mineral oil, 1.73 mmol). The reaction mixture was stirred at room temperature for 30 min before acetyl chloride (0.12 mL, 1.73 mmol) was added dropwise. After a further 30 min, the reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (2 x 20 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo to give the title compound as a ca. 3: 1 mixture (0.50 g) of product and 2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole-l,3,5,7(27/,67/)- tetraone which was used without further purification. 1H NMR (400 MHz, d6-DMSO) δ -0.03 (9H, s), 0.88 (2H, dd, J = 8.6 and 7.8 Hz), 2.58 (3H, s), 3.62 (2H, dd, J = 8.6 and 7.8 Hz), 5.02 (2H, s), 8.38 (2H, s).
Ethyl 6-( hydroxy methyl)- 1,3.5, 7-tetraoxo-3,5, 6,7-tetrahydropyrrolo[3,4f]isoindole-
To a stirred solution of ethyl l,3,5,7-tetraoxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,5,6,7- tctrahydropyrrolo[3,4;/]isoindolc-2( l /7)-carboxylatc (0.60 g, 1.43 mmol) in dichloromethane (16 mL) was added trifluoroacetic acid (4 mL). The reaction mixture was stirred at room temperature for 6 h, then concentrated in vacuo to afford the title compound as a colourless solid (0.44 g, 1.37 mmol, 96%). 1H NMR (400 MHz, d6-DMSO) δ 1.34 (3H, t, J = 7.1 Hz), 4.41 (2H, q, J = 7.1 Hz), 5.02 (2H, s), 8.34 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 13.9 (CH3), 60.8 (CH2), 63.6 (CH2), 118.6 (CH), 136.6 (C), 137.3 (C), 147.6 (C), 162.3 (C), 165.5 (C).
Ethyl l,3,5,7-tetraoxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,5,6,7- tetrahydropyrrolo[3,4-f]isoindole-2(1H)-carboxylate
To a stirred solution of 2-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.70 g, 2.02 mmol) in DMF (10 mL) was added sodium hydride (82.4 mg, 60% dispersion in mineral oil, 2.42 mmol). The reaction mixture was stirred at room temperature for 30 min before ethyl chloroformate (0.23 mL, 2.42 mmol) was added dropwise. After a further 1 h, the reaction mixture was quenched with water (50 mL) and extracted with ethyl acetate (2 x 30 mL). The combined organic layers were then dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the title compound as a colourless solid (0.69 g, 1.65 mmol, 82%). 1H NMR (400 MHz, d6-DMSO) δ -0.03 (9H, s), 0.88 (2H, dd, J = 8.9 and 7.3 Hz), 1.34 (3H, t, J = 7.1 Hz), 3.62 (2H, dd, J = 8.9 and 7.3 Hz), 4.41 (2H, q, J = 7.1 Hz), 5.01 (2H, s), 8.35 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ -1.4 (CH3), 13.9 (CH3), 17.3 (CH2), 63.4 (CH2), 66.3 (CH2), 67.0 (CH2), 118.7 (CH), 136.5 (C), 137.2 (C), 147.6 (C), 162.2 (C), 165.9 (C); ESI-MS: m/z calcd for Ci9H22N2O7Si: 418.1196; found [M+Na]+: 441.1073.
2-(2,3-Dihydroxypropyl)-6-(hydroxymethyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)- tetraone (via Scheme 1)
To a stirred solution of 2-(2,3-dihydroxypropyl)-6-((2- (trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.09 g, 0.21 mmol) in dichloromethane (4 mL) was added trifluoroacetic acid (1 mL). The reaction mixture was stirred at room temperature for 18 h, then diluted with dichloromethane (10 mL). The organic layer was washed with sat. aq. sodium bicarbonate solution (10 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford the title compound as a colourless solid (0.06 g, 0.19 mmol, 88%). 1H NMR (400 MHz d6-DMSO) δ 3.35-3.44 (2H, m), 3.64 (2H, d, J = 6.4 Hz), 3.82-3.84 (1H, m), 4.69 (1H, brs), 4.96 (1H, d, J = 4.7 Hz), 5.01 (2H, d, J = 6.8 Hz), 6.53 (1H, t, J = 7.0 Hz), 8.25 (2H, m); 13C NMR (100 MHz, d6-DMSO) δ 42.3 (CH2), 60.7 (CH2), 64.0 (CH2), 68.3 (CH), 117.5 (CH), 136.7 (C), 137.3 (C), 165.8 (C), 166.4 (C); ESI-MS: m/z calcd for CI4HI2N2O7: 320.0645; found [M+Na]+: 343.0542.
2-(2,3-Dihydroxypropyl)-6-(hydroxymethyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)- tetraone (via Scheme 2)
A stirred mixture of 2-(2,3-dihydroxypropyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.20 g, 0.69 mmol) and paraformaldehyde (41.4 mg, 1.38 mmol) in DMF (5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture, and was then left to stand at room temperature for 18 h. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford compound the title compound as a colourless solid (0.13 g, 0.39 mmol, 57%). 1H NMR (400 MHz d6-DMSO) 5 3.35-3.44 (2H, m), 3.64 (2H, d, J = 6.4 Hz), 3.82-3.84 (1H, m), 4.69 (1H, brs), 4.96 (1H, d, J = 4.7 Hz), 5.01 (2H, d, J = 6.8 Hz), 6.53 (1H, t, J = 7.0 Hz), 8.25 (2H, m); 13C NMR (100 MHz, d6-DMSO) δ 42.3 (CH2), 60.7 (CH2), 64.0 (CH2), 68.3 (CH), 117.5 (CH), 136.7 (C),
137.3 (C), 165.8 (C), 166.4 (C); ESI-MS: m/z calcd for CI4HI2N2O7: 320.0645; found [M+Na]+: 343.0542.
A stirred mixture of pyromellitic imide anhydride (1.00 g, 4.61 mmol) and 3-aminopropane- 1,2-diol (0.39 mL, 5.07 mmol) in DMF (15 mL) was heated at 50 °C for 42 h. After cooling to room temperature, water (100 mL) was added to the reaction mixture, and was then left to stand at room temperature for 48 h. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (0.19 g, 0.67 mmol, 15%). 1H NMR (400 MHz d6-DMSO) δ 3.38 (1H, dd, J = 11.0 and 6.0 Hz), 3.44 (1H, dd, J = 11.0 and 5.3 Hz), 3.66 (2H, d, J = 6.4 Hz), 3.85 (1H, pentet, J = 6.0 Hz), 4.70 (1H, brs), 4.98 (1H, brs), 8.16 (2H, s), 11.84 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 42.2 (CH2), 64.1 (CH2), 68.3 (CH), 117.1 (CH), 137.0 (C), 137.9 (C), 166.4 (C), 167.6 (C); ESI-MS: m/z calcd for CI3HI0N2O6: 290.0539; found [M+Na]+: 313.0432.
2-(2,3-Dihydroxypropyl)-6-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3, 4-f] isoindole-
A mixture of ethyl 1,3, 5,7 -tetraoxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3, 5,6,7- tetrahydropyrrolo[3,4-f|isoindole-2(177)-carboxylate (0.13 g, 0.31 mmol) and 3- aminopropane-l,2-diol (0.037 mL, 0.47 mmol) in tetrahydrofuran (5 mL) was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo then diluted with ethyl acetate (20 mL) and washed with water (30 mL). The aqueous layer was repeatedly extracted with ethyl acetate (3 x 20 mL). The combined organic layers were then dried over anhydrous
MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (EtOAc, neat) afforded the title compound as a colourless solid (0.06 g, 0.14 mmol, 46%). 1H NMR (400 MHz, d6-DMSO) δ 0.00 (9H, s), 0.88 (2H, dd, J = 8.3 and 7.3 Hz), 3.34-3.46 (2H, m), 3.61 (1H, d, J = 8.0 Hz), 3.64 (1H, d, J = 6.6 Hz), 3.83 (1H, pentet, J = 5.9 Hz), 4.69 (1H, t, J = 5.7 Hz), 4.96 (1H, d, J = 5.1 Hz), 5.01 (2H, s), 8.27 (2H, s); 13C NMR (100 MHz, d6- DMSO) δ -1.4 (CH3), 17.3 (CH2), 42.3 (CH2), 64.1 (CH2), 66.3 (CH2), 67.0 (CH2), 68.3 (CH), 117.6 (CH), 136.6 (C), 137.4 (C), 166.2 (C), 166.3 (C); ESI-MS: m/z calcd for Ci9H24N2O7Si: 420.1353; found [M+Na]+: 443.1245.
A stirred mixture of 2-(l,3-dihydroxypropyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.22 g, 0.74 mmol) and paraformaldehyde (44.5 mg, 1.48 mmol) in DMF (5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture, and was then left to stand at room temperature for 18 h. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (0.11 g, 0.34 mmol, 46%). 1H NMR (400 MHz d6-DMSO) δ 3.65-3.71 (2H, m), 3.80-3.86 (2H, m), 4.25-4.32 (1H, m), 4.91 (2H, dd, J = 6.9 and 5.2 Hz), 5.02 (2H, d, J = 7.1 Hz), 6.53 (1H, t, J = 7.1 Hz), 8.24 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 57.3 (CH), 58.1 (CH2), 60.7 (CH2), 117.4 (CH), 136.8 (C), 137.1 (C), 165.8 (C), 166.6 (C).
A stirred mixture of pyromellitic imide anhydride (1.00 g, 4.61 mmol) and 2-aminopropane- 1,3-diol (0.39 mL, 5.07 mmol) in DMF (15 mL) was heated at 100 °C for 18 h. The reaction
mixture was stirred for a further 3 h at 150 °C. After cooling to room temperature, water (100 mL) was added to the reaction mixture, and was then left to stand at room temperature for 18 h. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (1.00 g, 3.45 mmol, 75%). 1H NMR (400 MHz d6-DMSO) δ 3.64-3.70 (2H, m), 3.79-3.85 (2H, m), 4.24-4.32 (1H, m), 4.90 (2H, t, J = 6.0 Hz), 8.14 (2H, s), 11.83 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 57.2 (CH), 58.1 (CH2), 117.0 (CH), 136.8 (C), 137.9 (C), 166.7 (C), 167.6 (C); ESI-MS: m/z calcd for C13H10N2O6: 290.0539; found [M+Na]+: 313.0426.
Methyl 3-hydroxy-2-(6-(hydroxymethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- f]isoindol-2(1H)-yl)propanoate
A stirred mixture of methyl 3-hydroxy-2-(l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- /|isoindol-2(1H)-yl)propanoate (0.25 g, 0.79 mmol) and paraformaldehyde (47.2 mg, 1.57 mmol) in DMF (5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (3 x 20 mL). The organic layer was then dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded the title compound as a colourless solid (0.14 g, 0.41 mmol, 53%). 1H NMR (400 MHz, d6-DMSO) δ 4.00-4.04 (2H, m), 5.03 (2H, d, J = 7.1 Hz), 5.07 (1H, dd, J = 8.5 and 6.5Hz), 5.15 (1H, t, J = 6.5 Hz), 6.56 (1H, t, J = 7.1 Hz), 8.33 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 52.5 (CH3), 54.4 (CH), 57.8 (CH2), 60.7 (CH2), 118.1 (CH), 136.5 (C), 137.3 (C), 165.6 (C), 165.7 (C), 167.6 (C).
A mixture of serine methyl ester hydrochloride (0.86 g, 5.53 mmol) and triethylamine (0.77 mL, 5.53 mmol) in DMF (10 mL) was stirred at room temperature for 30 min, before pyromellitic imide anhydride (1.0 g, 4.61 mmol) was added. The reaction mixture was then stirred at 100 °C for 18 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (2 x 20 mL). The organic layer was concentrated in vacuo to afford the title compound as a brown foam (0.30 g, 0.94 mmol, 20%). 1H NMR (400 MHz, d6-DMSO) δ 3.66 (3H, s), 4.00-4.04 (2H, m), 5.06 (1H, dd, J = 8.5 and 6.4 Hz), 5.14 (1H, t, 7 = 6.1 Hz), 8.22 (2H, s), 11.87 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 52.5 (CH3), 54.3 (CH), 57.8 (CH2), 117.7 (CH), 136.2 (C), 138.4 (C), 165.6 (C), 167.5 (C), 167.6 (C).
To a stirred mixture of pyromellitic diimide (2.00 g, 9.25 mmol) in DMF (200 mL) was added sodium hydride (0.22 g, 60% dispersion in mineral oil, 9.25 mmol). The reaction mixture was stirred at room temperature for 30 min before ethyl chloroformate (0.88 mL, 9.25 mmol) was added dropwise, and the reaction stirred for a further 1 h. 2-Methoxyethan-l -amine (0.80 mL, 9.25 mmol) was then slowly added, and the reaction mixture heated at 50 °C for 18 h. After cooling to room temperature, the reaction mixture was quenched with water (200 mL) and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were then washed with brine (3 x 200 mL), dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded the title compound as a colourless solid (0.30 g, 1.11 mmol, 24%). 1H NMR (400 MHz, d6-DMSO) δ 3.24 (3H, s), 3.57 (2H, t, J = 5.7 Hz), 3.80 (2H, t, J = 5.7 Hz), 8.15 (2H, s), 11.83 (1H, brs); 13C NMR (100 MHz, d6-DMSO) δ 37.4 (CH2), 57.8 (CH3), 68.4 (CH2), 117.3 (CH), 136.7 (C), 138.0 (C), 166.2 (C), 167.5 (C).
2-(Hydroxymethyl)-6-(2-(methylthio)ethyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)- tetraone
A stirred mixture of 2-(2-(methylthio)ethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.45 g, 1.55 mmol) and paraformaldehyde (93.1 mg, 3.10 mmol) in DMF (10 mL) was heated at 80 °C for 18 h. After cooling to room temperature, the reaction mixture was dried in vacuo to afford the title compound as a pale-yellow oil (0.40 g, 1.25 mmol, 81%). 1H NMR (400 MHz d6-DMSO) δ 2.11 (3H, s), 2.78 (2H, t, J = 6.8 Hz), 3.84 (2H, t, J = 6.8 Hz), 5.02 (2H, d, J = 7.0 Hz), 6.53 (1H, t, J = 7.0 Hz), 8.27 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 14.3 (CH3), 31.0 (CH2), 36.7 (CH2), 60.7 (CH2), 117.7 (CH), 136.9 (C), 137.0 (C), 165.8 (C), 166.0 (C).
A stirred mixture of pyromellitic imide anhydride (1.00 g, 4.61 mmol) and 2- (methylthio)ethylamine (0.51 mL, 5.53 mmol) in DMF (10 mL) was heated at 100 °C for 18 h. The reaction mixture was stirred for a further 1 h at 150 °C. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (20 mL) and washed with water (2 x 20 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 7:3) afforded the title compound as a pale-yellow solid (0.54 g, 1.87 mmol, 41%). 1H NMR (400 MHz, d6-DMSO) δ 2.10 (3H, s), 2.78 (2H, t, J = 6.8 Hz), 3.84 (2H, t, J = 6.8 Hz), 8.17 (2H, s), 11.83 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 14.2 (CH3), 31.0 (CH2), 36.6 (CH2), 117.3 (CH), 136.7 (C), 138.1 (C), 166.1 (C), 167.5 (C).
2-(Hydroxymethyl)-6-(2-(methylsulfonyl)ethyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)- tetraone
A stirred mixture of 2-(2-(methylsulfonyl)ethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)- tetraone (0.90 g, 2.79 mmol) and paraformaldehyde (168 mg, 5.59 mmol) in DMF (15 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a beige solid (0.70 g, 1.99 mmol, 71%). 1H NMR (500 MHz d6-DMSO) δ 3.08 (3H, s), 3.52 (2H, t, J = 6.9 Hz), 4.07 (2H, t, J = 6.9 Hz), 5.01 (2H, brs), 6.54 (1H, brs), 8.29 (2H, s); 13C NMR (125 MHz, d6-DMSO) δ 31.7 (CH2), 40.4 (CH3), 50.6 (CH2), 60.7 (CH2), 117.8 (CH), 137.0 (C), 137.1 (C), 165.8 (C).
A mixture of 2-aminoethylmethylsulfone hydrochloride (0.88 g, 5.53 mmol) and triethylamine (0.77 mL, 5.53 mmol) in DMF (10 mL) was stirred at room temperature for 30 min, before pyromellitic imide anhydride (1.0 g, 4.61 mmol) was added. The reaction mixture was then stirred at 100 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a grey solid (1.20 g, 3.72 mmol, 81%). 1H NMR (500 MHz, d6-DMSO) δ 3.08 (3H, s), 3.52 (2H, t, J = 6.7 Hz), 4.07 (2H, t, J = 6.7 Hz), 8.19 (2H, s), 11.85 (1H, s); 13C NMR (125 MHz, d6-DMSO) δ 32.0 (CH2), 40.7 (CH3), 51.0 (CH2), 117.8 (CH), 137.2 (C), 138.5 (C), 166.3 (C), 167.9 (C).
2-(2-(Dimethylamino)ethyl)-6-((2-(trimethylsilyl)ethoxy)methyl)pyrrolo[3,4-f]isoindole-
To a stirred solution of ethyl l,3,5,7-tetraoxo-6-((2-(trimethylsilyl)ethoxy)methyl)-3,5,6,7- tetrahydropyrrolo[3,4-f|isoindole-2(1H)-carboxylate (0.30 g, 0.72 mmol) in THF (15 mL) was added N,N-dimcthylcthylcncdiaminc (0.078 mL, 0.71 mmol), and the reaction mixture stirred at 40 °C for 6 h. The reaction mixture was then concentrated in vacuo. Purification by flash column chromatography (CH2Cl2/MeOH, 9:1) afforded the title compound as a yellow oil (0.27 g, 0.65 mmol, 90%). 1H NMR (400 MHz, d6-DMSO) δ -0.03 (9H, s), 0.86-0.90 (2H, m), 2.17 (6H, s), 2.50-2.54 (2H, m), 3.59-3.63 (2H, m), 3.73 (2H, t, J = 6.4 Hz), 5.01 (2H, s), 8.27 (2H, s); 13C NMR (400 MHz, d6-DMSO) δ -1.4 (CH3), 17.3 (CH2), 36.1 (CH2), 56.2 (CH2), 66.3 (CH2), 66.9 (CH2), 117.7 (CH), 136.8 (C), 137.1 (C), 166.1 (C), 166.2 (C).
A stirred mixture of 2-benzylpyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (2.00 g, 6.53 mmol) and paraformaldehyde (0.29 g, 9.66 mmol) in DMF (30 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (60 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (30 mL), then dried in vacuo to afford the title compound as a beige solid (1.68 g, 5.00 mmol, 77%). 1H NMR (400 MHz, d6-DMSO) δ 4.83 (2H, s), 5.02 (2H, d, J = 7.1 Hz), 6.53 (1H, t, J = 7.1 Hz), 7.27-7.37 (5H, m), 8.27 (2H, s); 13C NMR (400 MHz, d6-DMSO) δ 41.4 (CH2), 60.7 (CH2), 177.8 (CH), 127.5 (CH), 127.6 (CH), 128.6 (CH), 136.1 (C), 136.8 (C), 137.2 (C), 165.8 (C), 166.1 (C).
To a stirred solution of pyromellitic imide anhydride (2.00 g, 9.21 mmol) in DMF (25 mL) at 0 °C was added benzylamine (1.10 mL, 10.1 mmol) dropwise, then the reaction mixture was heated at 100 °C for 18 h. After cooling to room temperature, the insoluble by-products were filtered off, and water (60 mL) was added to the filtrate. The precipitated solids were collected by filtration, washed with water (30 mL), then dried in vacuo to afford the title compound as a beige solid (2.20 g, 7.18 mmol, 78%). 1H NMR (400 MHz, d6-DMSO) δ 4.82 (2H, s), 7.26- 7.36 (5H, m), 8.17 (2H, s), 11.84 (1H, brs); 13C NMR (400 MHz, d6-DMSO) δ 41.3 (CH2), 117.4 (CH), 127.5 (CH), 128.6 (CH), 136.2 (C), 136.8 (C), 138.1 (C), 166.2 (C), 167.7 (C).
A stirred mixture of 2-(pyridin-2-ylmethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.37 g, 1.19 mmol) and paraformaldehyde (71.3 mg, 2.38 mmol) in DMF (7.5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (0.23 g, 0.67 mmol, 56%). 1H NMR (400 MHz, d6-DMSO) δ 4.97 (2H, s), 5.03 (2H, d, J = 7.1 Hz), 6.55 (1H, t, J = 7.1 Hz), 7.29 (1H, ddd, 7 = 7.5, 4.9 and 1.0 Hz), 7.47 (1H, d, J = 7.9 Hz), 7.78 (1H, td, J = 11.5 and 1.8 Hz), 8.44 (2H, s), 8.44 (1H, ddd, J = 4.8, 1.7 and 0.9 Hz); 13C NMR (100 MHz, d6-DMSO) δ 42.6 (CH2), 60.7 (CH2), 117.9 (CH), 121.5 (CH), 122.7 (CH), 136.9 (C), 137.0 (C), 137.2 (CH), 149.1 (CH), 154.6 (C), 165.8 (C), 166.1 (C).
A stirred mixture of pyromellitic imide anhydride (1.10 g, 5.07 mmol) and 2- (aminomethyl)pyridine (0.60 g, 5.57 mmol) in DMF (10 mL) was heated at 100 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL) and dried in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded the title compound as a colourless solid (0.39 g, 1.27 mmol, 25%). 1H NMR (400 MHz, d6-DMSO) δ 4.97 (2H, s), 7.28 (1H, ddd, J = 7.5, 4.9 and 1.1 Hz), 7.46 (1H, d, J = 7.9 Hz), 7.78 (1H, td, J = 11.6 and 1.8 Hz), 8.19 (2H, s), 8.43 (1H, ddd, 7 = 4.9, 1.8 and 1.0 Hz), 11.85 (1H, brs); 13C NMR (100 MHz, d6-DMSO) δ 42.5 (CH2), 117.4 (CH), 121.5 (CH), 122.6 (CH), 136.8 (C), 136.9 (CH), 138.3 (C), 149.1 (CH), 154.6 (C), 166.2 (C), 167.8 (C).
A stirred solution of 2-(l, 3,5, 7-tetraoxo-3, 5,6,7 -tetrahydropyrrolo[3,4-f|isoindol-2(1H)- yl)acetic acid (0.30 g, 1.09 mmol) and paraformaldehyde (50.0 mg, 1.67 mmol) in DMF (10 mL) was heated at 80 °C for 18 h. After cooling to room temperature, the reaction mixture was dried in vacuo to afford the title compound as a beige solid (0.30 g, 0.99 mmol, 91%). 1H NMR (400 MHz, d6-DMSO) δ 4.39 (2H, s), 5.02 (2H, d, J = 7.0 Hz), 6.55 (1H, t, J = 7.1 Hz), 8.33 (2H, s), 13.36 (1H, brs); 13C NMR (400 MHz, d6-DMSO) δ 39.5 (CH2), 60.7 (CH2), 118.1 (CH), 136.8 (C), 137.2 (C), 165.5 (C), 165.7 (C), 168.5 (C).
To a stirred solution of pyromellitic imide anhydride (0.75 g, 3.45 mmol) in DMF (10 mL) at 0 °C was added glycine (0.29 g, 3.86 mmol), then the reaction mixture was heated at 100 °C for 18 h. After cooling to room temperature, water (10 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (10 mL), then dried in vacuo to afford the title compound as a colourless solid (0.46 g, 1.68 mmol, 49%). 1H NMR (400 MHz, d6-DMSO) δ 4.39 (2H, s), 8.22 (2H, s), 11.86 (1H, s), 13.33 (1H, brs); 13C NMR (400 MHz, d6-DMSO) δ 39.5 (CH2), 117.7 (CH), 136.5 (C), 138.4 (C), 165.6 (C), 167.5 (C), 168.5 (C).
Methyl 2-(6-( hydroxy methyl)- 1,3.5, 7-tetraoxo-3,5, 6,7-tetrahydropyrrolo|3,4-f]isoindol-
A stirred mixture of methyl 2-(l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f|isoindol- 2(1H)-yl)acetate (0.25 g, 0.87 mmol) and paraformaldehyde (52.1 mg, 1.73 mmol) in DMF (7.5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a yellow solid (0.12 g, 0.38 mmol, 43%). 1H NMR (400 MHz d6-DMSO) δ 3.71 (3H, s), 4.52 (2H, s), 5.02 (2H, d, J = 7.1 Hz), 6.55 (1H, t, J = 7.1 Hz), 8.33 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 39.1 (CH2), 52.6 (CH3), 60.7 (CH2), 118.2 (CH), 136.7 (C), 137.3 (C), 165.4 (C), 165.7 (C), 167.7 (C).
Methyl 2-(l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)-yl)acetate
A mixture of glycine methyl ester hydrochloride (0.64 g, 5.07 mmol) and triethylamine (0.71 mL, 5.07 mmol) in DMF (10 mL) was stirred at room temperature for 30 min, before pyromellitic imide anhydride (1.00 g, 4.61 mmol) was added. The reaction mixture was then stirred at 50 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL) and dried in vacuo. Purification by flash column chromatography (petroleum ether/EtOAc, 1:1) afforded the title compound as a pale-yellow solid (0.27 g, 0.94 mmol, 20%). 1H NMR (400 MHz, d6-DMSO) δ 3.71 (3H, s), 4.52 (2H, s), 8.23 (2H, s), 11.87 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 38.9 (CH2), 52.6 (CH3), 117.8 (CH), 136.4 (C), 138.4 (C), 165.5 (C), 167.4 (C), 167.7 (C).
2-(6-(Hydroxymethyl)-l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4-f]isoindol-2(lH)- yl)-N,N -dimethylacetamide
A stirred mixture of N,N-dimethyl-2-(l,3,5,7-tetraoxo-3,5,6,7-tetrahydropyrrolo[3,4- |isoindol-2(177)-yl)acetamide (0.30 g, 1.00 mmol) and paraformaldehyde (59.8 mg, 1.99 mmol) in DMF (5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (0.21 g, 0.63 mmol, 64%). 1H NMR (400 MHz d6-DMSO) δ 2.85 (3H, s), 3.09 (3H, s), 4.58 (2H, s), 5.02 (2H, d, J = 7.1 Hz), 6.54 (1H, t, J = 7.1 Hz), 8.31 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 35.2 (CH3), 35.8 (CH3), 39.5 (CH2), 60.7 (CH2), 117.9 (CH), 137.0 (C), 137.2 (C), 164.9 (C), 165.8 (C), 165.9 (C). N,N -I)imethyl-2-( L3.5,7-tetraoxo-3.5,6,7-tetrahydropyrrolo|3.4-f]isoindol-2(1H)- yl)acetamide
A stirred mixture of pyromellitic imide anhydride (1.00 g, 4.61 mmol) and 2-amino- N,N- dimethylacetamide (0.56 g, 5.53 mmol) in DMF (20 mL) was heated at 100 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (0.50 g, 1.66 mmol, 36%). 1H NMR (400 MHz, d6-DMSO) δ 2.84 (3H, s), 3.09 (3H, s), 4.57 (2H, s), 8.20 (2H, s), 11.85 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 35.2 (CH3), 35.8 (CH3), 39.5 (CH2), 117.5 (CH), 136.7 (C), 138.3 (C), 164.9 (C), 166.0 (C), 167.5 (C).
A stirred mixture of 2-(2,5,8,l l,14-pentaoxahexadecan-16-yl)pyrrolo[3,4-f|isoindole- l,3,5,7(2H,6H)-tetraone (0.45 g, 1.00 mmol) and paraformaldehyde (60.0 mg, 2.00 mmol) in DMF (10 mL) was heated at 80 °C for 18 h. After cooling to room temperature, the reaction mixture was dried in vacuo to afford the title compound as a colourless oil (0.44 g, 0.92 mmol, 92%). 1H NMR (400 MHz d6-DMSO) δ 3.25 (3H, s), 3.42-3.55 (16H, m), 3.68 (2H, t, J = 6.0 Hz), 3.82 (2H, t, J = 5.8 Hz), 5.04 (2H, brs), 6.55 (1H, brs), 8.28 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 37.7 (CH2), 58.0 (CH3), 60.6 (CH2), 66.8 (CH2), 69.5 (CH2), 69.6 (CH2), 69.7 (CH2), 71.2 (CH2), 117.6 (CH), 136.9 (C), 137.1 (C), 165.8 (C), 166.1 (C).
2-(2,5,8,ll,14-Pentaoxahexadecan-16-yl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)-tetraone
A stirred mixture of pyromellitic imide anhydride (0.50 g, 2.30 mmol) and 2,5,8,11,14- pentaoxahexadecan-16-amine (0.58 g, 2.30 mmol) in DMF (5 mL) was heated at 80 °C for 18 h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with water (30 mL). The organic layer was washed with brine (2 x 30 mL), dried over anhydrous MgSO4, filtered and then concentrated in vacuo to afford the title compound as a colourless solid (0.47 g, 1.05 mmol, 46%). 1H NMR (400 MHz, d6-DMSO) δ 3.22 (3H, s), 3.40-3.53 (16H, m), 3.65 (2H, t, J = 5.9 Hz), 3.80 (2H, t, J = 6.0 Hz), 8.15 (2H, s), 11.83 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 37.7 (CH2), 58.0 (CH3), 66.8 (CH2), 69.4 (CH2), 69.5 (CH2), 69.6 (CH2), 69.7 (CH2), 71.2 (CH2), 117.3 (CH), 136.8 (C), 138.0 (C), 166.1 (C), 167.5 (C); ESI-MS: m/z calcd for C2IH26N2O9: 450.1638; found [M+Na]+: 473.1520.
To a stirred solution of pyromellitic imide anhydride (2.00 g, 9.21 mmol) in DMF (25 mL) at 0 °C was added ethanolamine (0.56 mL, 9.28 mmol) dropwise, then the reaction mixture was heated at 100 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (40 mL), then dried in vacuo to afford the tile compound as a colourless solid (1.71 g, 6.57 mmol, 71%). 1H NMR (400 MHz, d6-DMSO) δ 3.59-3.64 (2H, m), 3.68-3.71 (2H, m), 4.85-4.88 (1H, m), 8.14 (2H, s), 11.82 (1H, brs); 13C NMR (400 MHz, d6-DMSO) δ 40.9 (CH2), 57.8 (CH2), 117.1 (CH), 137.0 (C), 137.9 (C), 166.4 (C), 167.6 (C).
A stirred mixture of pyromellitic diimide (1 g, 4.63 mmol) and paraformaldehyde (111 mg, 3.70 mmol) in DMF (100 mL) was heated at 80 °C for 18 h. After cooling to room temperature, the reaction mixture was concentrated in vacuo. Purification by flash column chromatography
(petroleum ether/EtOAc, 19:1) afforded the title compound as a colourless solid (170 mg, 0.69 mmol, 15%). 1H NMR (400 MHz, d6-DMSO) δ 5.01 (2H, d, J = 7.1 Hz), 6.52 (1H, t, J = 7.1 Hz), 8.20 (2H, s), 11.9 (1H, s); 13C NMR (100 MHz, d6-DMSO) δ 60.6 (CH2), 117.6 (CH), 116.7 (C), 138.2 (C), 165.8 (C), 167.5 (C).
To a solution of pyromellitic dianhydride (20 g) in tetrahydrofuran (200 mL) at room temperature was added water (11.4 mL), and the reaction stirred at room temperature for a further 15 min. After cooling to 0 °C, anhydrous magnesium sulfate (68.8 g) was added and the reaction stirred at 0 °C for a further 15 minutes, before allowing to warm to room temperature. After a further 30 minutes at room temperature the reaction mixture was filtered, and the collected solid washed with tetrahydrofuran (2 x 100 mL). The filtrate was then cooled to 0 °C and saturated with anhydrous ammonia gas - rapidly forming a precipitate (at which point 200 mL of acetone was added to increase the efficiency of the stirring - and the mixture then re-saturated with further ammonia gas). After stirring at 0 °C for a further 20 minutes the insoluble material was then collected by filtration, washed with acetone and dried in vacuo to afford 2,4,5-tricarboxybenzamide as a white solid (24.6 g), which was used without further purification.
A solution of 2,4,5-tricarboxybenzamide (24.6 g) in thionyl chloride (200 mL) was heated at reflux for 2 hours. Upon cooling, hexane (200 mL) was added and the mixture stirred at room temperature for a further 30 minutes. The insoluble material was then collected by filtration, washed thoroughly with hexane, followed by ice-cold DMF:toluene (200 mL, 1:4 v/v) to remove the impurities (pyromellitic dianhydride and pyromellitic diimide). The resulting solid was then dissolved in acetone (400 mL) and any insoluble salts were filtered off. The collected filtrate was then reduced in vacuo to afford the title compound as a light beige solid (16.4 g).
2-(2-Hydroxyethyl)-6-(hydroxymethyl)pyrrolo[3,4-f]isoindole-l,3,5,7(2H,6H)-tetraone
A stirred mixture of 2-(2-hydroxyethyl)pyrrolo[3,4-f|isoindole-l,3,5,7(2H,6H)-tetraone (0.50 g, 1.92 mmol) and paraformaldehyde (87.0 mg, 2.90 mmol) in DMF (10 mL) was heated at 80 °C for 18 h. After cooling to room temperature, water (50 mL) was added to the reaction mixture. The precipitated solids were collected by filtration, washed with water (50 mL), then dried in vacuo to afford the title compound as a colourless solid (0.33 g, 1.14 mmol, 59%). 1H NMR (400 MHz d6-DMSO) δ 3.59-5.64 (2H, m), 3.69-3.72 (2H, m), 4.86 (1H, t, J = 6.0 Hz), 5.02 (2H, d, J = 7.0 Hz), 6.52 (1H, t, J = 7.1 Hz), 8.25 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 40.9 (CH2), 57.8 (CH3), 60.7 (CH2), 117.5 (CH), 136.8 (C), 137.3 (C), 165.8 (C), 166.3 (C).
To a solution of pyromellitic dianhydride (1.00 g, 4.58 mmol) in DMF (50 mL) was added slowly ethanolamine (280 mg, 4.58 mmol) in DMF (5 mL) and 3 -aminopropane- 1,2-diol (418 mg, 4.58 mmol) in DMF (5 mL). The reaction mixture then was heated at 100 °C for 18 h, before being diluted with water (100 mL). The precipitated solids were then collected by filtration, washed with water (3 x 50 mL), then dried in vacuo. Purification by flash column chromatography (CH2CI2/McOH, 9:1) afforded the title compound as a colourless solid (100 mg, 0.30 mmol, 7%). 1H NMR (400 MHz, d6-DMSO) δ 3.34-3.46 (2H, m), 3.60-3.65 (4H, m), 3.70 (2H, t, J = 5.3 Hz), 3.80-3.88 (1H, m), 4.68 (1H, t, J = 5.6 Hz), 4.87 (1H, t, J = 6.1 Hz), 4.96 (1H, d, J = 5.1 Hz), 8.20 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 40.9 (CH2), 42.3 (CH2), 57.8 (CH2), 64.1 (CH2), 68.3 (CH), 117.0 (CH), 137.0 (2 x C), 166.39 (C), 166.44 (C).
2-(2,3-Dihydroxypropyl)-6-(l-hydroxypropan-2-yl)pyrrolo[3,4-f]isoindole-
1 ,3,5,7 (2H,6H ) -tetraone
To a solution of pyromellitic dianhydride (1.00 g, 4.58 mmol) in DMF (50 mL) was added slowly 2-amino-l -propanol (344 mg, 4.58 mmol) in DMF (5 mL) and 3 -aminopropane- 1,2- diol (418 mg, 4.58 mmol) in DMF (5 mL). The reaction mixture was then heated at 100 °C for 18 h, before being diluted with water (100 mL). The precipitated solids were then collected by filtration, washed with water (3 x 50 mL), then dried in vacuo. Purification by flash column chromatography (EtOAc, neat) afforded the title compound as a colourless solid (45 mg, 0.129 mmol, 3%). 1H NMR (400 MHz, d6-DMSO) δ 1.35 (3H, d, J = 7.1 Hz), 3.34-3.45 (2H, m), 3.53-3.58 (1H, m), 3.64 (2H, d, J = 6.5 Hz), 3.82-3.88 (2H, m), 4.26-4.35 (1H, m), 4.70 (1H, t, J = 5.7 Hz), 4.97 (1H, dd, J = 6.8 and 5.4 Hz), 4.98 (1H, d, J = 5.2 Hz), 8.18 (2H, s); 13C NMR (100 MHz, d6-DMSO) δ 14.3 (CH3), 42.3 (CH), 49.8 (CH2), 61.7 (CH2), 64.1 (CH2), 68.3 (CH), 116.9 (CH), 136.8 (C), 137.0 (C), 166.49 (C), 166.52 (C).
In vitro studies
The compounds of the present invention were initially screened for activity using an in vitro fully automated incubation system for the measurement of total gas production and gas composition (methane and hydrogen). The system used is described in detail in the paper by Muetzel et al. (2014; Animal Feed Science and Technology 196, 1-11). The system in this specification is referred to as the rumen in vitro system or RIV. The RIV system provides a relatively simple tool for determining the rate and production of methane and also whether the rate and production of methane is inhibited or reduced by a particular compound or feed.
Rumen in vitro assay method.
Rumen in vitro assays use rumen fluid from donor animals (typically either sheep or cattle) which is typically combined with a buffer and then incubated in sealed fermentation vessels at 39 °C for either 24 or 48 h. These assays systems have been well-characterised and used by the scientific community over the last two decades (Rymer et al. 2005). The system that has been used here to characterise the effects of inhibitors on methane production and gas production, and the formation of H2, was described by Muetzel et al. (2014). Rumen in vitro assay systems reflect what can occur in the rumen in vivo, but only short-term, due to their short incubation times (typically not exceeding 48 h) which is limited by its buffering capacity and the fact that it is a closed system.
Stock solutions of inhibitors were re-suspended in dimethylformamide (DMF) at concentrations 1000-fold higher than the highest used for the assays. Any further dilutions were also prepared using DMF. The total amount of inhibitor solution added to the rumen fluidbuffer mixture (60 mL) was 60 pl. Incubations used 60 ml of medium containing 12 ml of filtered rumen fluid and 48 ml of buffer in serum bottles for 24-48 h, essentially as described by Muetzel et al. (2014). Two fistulated cattle were used as donor animals for rumen fluid and treatments were incubated in duplicate bottles. Sets of duplicate incubation vials that contained rye grass (with rumen fluid -buffer mixture), and rye grass with 30 pM bromoethanesulfonate (BES) were also incubated as negative and positive controls, respectively. One experiment consists of 2 replicates of an inhibitor at any one concentration run at the same time, and a run can contain up to 32 bottle, including positive (30 pM BES) and negative (no inhibitor added) controls.
Compound 12, for example, was tested using the 60 mL rumen in vitro assay system at 100 pM and 2 pM final concentrations and compared to a positive control with 30 pM BES. At 30 pM and 2 pM, inhibition levels were approximately 86.4 % and 16.6 % at 18 h, respectively.
Other compounds of Formula I were tested in the RIV using the same method. All the compounds were either sourced commercially from chemical supply companies or synthesised by chemical synthesis companies. It can be seen from the results of the RIV experimentation tabulated below, and the subsequent results of the in vivo testing that is described below, that the RIV results for the compounds of Formula I are somewhat predictive of in vivo activity.
In vivo studies
The animal experiments described in this specification were all reviewed and approved by the Grasslands Animal Ethics Committee (Palmerston North, NZ) and all animals were cared for according the Code of Ethical Conduct (Animal Welfare Act, 1999) and its amendments.
Example 1
Toxicity testing in mice
The potential toxicology for Compound 12 was tested according to OECD 423. Mice testing used two groups with three mice (female Swiss mice, non-pregnant), all at approximately 8-9 weeks of age. On the day of testing, food was withdrawn 1-2 hours prior to dosing. Following fasting, the animals were weighed and the test substances administered. Access to food was resumed 1-2 hours after administration of the compounds. The compounds were administered in a single dose by oral gavage in corn oil (maximum of 0.3 ml per dose) at the selected dose
and the time recorded. The mice were observed individually after dosing at least once during the first 30 minutes, periodically over the first 24 hours, with special attention given to the first 4 hours, and then daily thereafter for a total of 14 days. The mice were weighed every seven days (0, 7 and 14 days). All observations were systematically recorded for each individual animal. These observations included (if present): tremors, convulsions, salivation, diarrhoea, lethargy, sleep, coma, and changes in fur, skin, eyes, mucus membranes, respiration, motor activity and behaviour. No adverse effects were noted for Compound 12 at 300 mg/kg.
In vivo trial methods
The trial for testing the effects of Compound 12 on methane emissions from sheep over a 48- hour period in methane measurement chambers was approved by the Grasslands Animal Ethics Committee, and the use of the compounds in animals by the New Zealand Food Safety Authority, as required under ACVM legislation. Three sheep were used for the Compound 12 treatment group. The animals received a general -purpose diet (GP) at 1.5 x maintenance energy requirements throughout the trials. Each 1000 g of GP diet consisted of the following proportions of 500 g hay, 100 g soybean meal, 290 g barley, 100 g molasses and 10 g mineral mix. During the time in the respiration chambers the animals had free access to water, with the feed offered twice a day at approximately 9:00 and 16:00 h in equal amounts. Feed refusals were weighed.
The animals were adapted to GP diet for 14 days prior to entering the methane measurement chambers.
After the 14-day acclimatisation period, methane emissions were measured in open circuit respiration chambers as described in Chapter 1 of the technical manual on respiration chamber design (http://www.globalresearchalliance.org/wp-content/uploads/2012/03/GRA-MAN- Facility-BestPract-2012-ch 13.pdf) . Dry matter intake (DMI, kg/d) was recorded during methane measurements from the weight difference of feed offered and refused. The first day in the chambers (24-hour period; Period 1 (Pl)) served as a control for each animal (to determine background methane emissions). For the next two days (Period 2 (P2)) the sheep received Compound 12 at 68 mg/day (evenly split between morning and afternoon feeds).
Results
Methane gas outputs for the 72-hour period (first 24 hours for background measurements, followed by two days of dosing once each morning) in open circuit respiration chambers were determined and are summarised in Table 1.
Table 1: Data for 2-day dosing with Compound 12. P2 values are the average of the first and second days of dosing.
It can be seen from the results that Compound 12 at 68 mg/day caused a 21.6% inhibition (e.g., average of three animals) reductions in methane emissions (CH4 g/day) and a 21.4% inhibition (e.g., average of three animals) reductions methane yield (g CH4/kg feed) in Period 2, respectively. There was no drop in feed intake and H2 was observed in the Compound 12- treated group compared to the background measurements, indicative of a direct and specific effect on methane-forming microorganisms.
The present invention and its embodiments have been described in detail. However, the scope of the present invention is not intended to be limited to the particular embodiments of the invention described in the specification. Various modifications, substitutions, and variations can be made to the disclosed material without departing from the spirit and/or essential characteristics of the present invention. Accordingly, one of ordinary skill in the art will readily appreciate from the disclosure that later modifications, substitutions, and/or variations performing substantially the same function or achieving substantially the same result as embodiments described herein may be utilized according to such related embodiments of the present invention. Thus, the following claims are intended to encompass within their scope modifications, substitutions, and variations to the embodiments of the invention disclosed herein.
Claims
Claims
1 A compound of Formula I
Formula I wherein R1 is selected from -H, -alkyl, alkyl-ONO2, or -ONO2; wherein X is different to R1 and is selected from -H, alkyl-ONO2, -ONO2 or a substituent of Formula II, Formula II
wherein each n is independently selected from 0, 1, 2, 3, 4, 5 or 6 and when n is 0, 1, 2, 3, 4, 5, 6 any adjacent carbons are optionally unsaturated to form a double or triple bond, wherein R2 is selected from -H, -alkyl, - alkyl-ONO2, -aryl, -heteroaryl or -heterocyclyl or - CO2R3; wherein -R1 and -R2 together form an optionally substituted aliphatic ring which is optionally saturated; wherein -Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -CO2R3, -C(=O)R3, - alkyl-OH, -(alkyl-OH)-alkyl-OH, -alkyl-(alkyl-OH)2, -alkyl-(alkyl-OH)3,
-(alkyl-O-alkyl)k, -(alkyl-O)k-L; -alkyl-(C=O)O-(alkyl-O)k-L; -alkyl-SH, -alkyl-S-alkyl, - alkyl-(S=O)-alkyl, -alkyl-(SO2)-alkyl; -alkyl-(SO2)-OH; -alkyl-(SO2)-NH2; -alkyl-(SO2)- NHalkyl, -alkyl-(SO2)-N(alkyl)2; -alkyl-(SO2)-NH(alkyl-O)k-L; -alkyl-(C=O)-NH2; -alkyl- (C=O)-NH(alkyl); -alkyl-(C=O)-N(alkyl)2; -alkyl-(C=O)-NH(alkyl-O)k-L; -alkyl heterocyclyl, wherein k is 1, 2, 3, 4, 5 or 6; and wherein L is -H, -alkyl;
wherein R3 is selected from -H, -alkyl, -NHalkyl, -N(alkyl)2 or aryl with the proviso that R3 is only selected from -H, -alkyl, or -aryl for -CO2R3; or
Z is a substituent of Formula III
Formula III wherein m is 0, 1, 2, 3 or 4, and when m is 0, 1, 2, 3 or 4, any adjacent carbons are optionally unsaturated to form a double or triple bond; Y is selected from -CH2-, -O-, -C(=O)- -S-, -S(=O)- , -SO2-, -NH- or -N(alkyl)- p is selected from 0, or 1 ;
R4 when present is selected from -H, -alkyl, or -alkyl- ONO2;
R5 when present is selected from -H, -OH, -O-alkyl, -NH2, -alkyl, -NH(alkyl), -N(alkyl)2, - ONO2, -alkyl-ONO2, -aryl, -heteroaryl, -heterocyclyl, -C(= O)R3 or - CO2R3; or or a salt thereof.
2 The compound of Formula I as claimed in claim 1, which includes at least one -ONO2 substituent.
3 The compound of Formula I, as claimed in claim 1 or claim 2, wherein Ri is -H, X is - ONO2 and Z is a compound of Formula III.
4 The compound of Formula I as claimed in claim 1 , wherein Z is Formula III, R4 is selected from -H or -alkyl-ONO2 and R5 is selected from -H, -O-alkyl, -ONO2, -CO2-alkyl or aryl.
5 The compound of Formula I as claimed in claim 1 or claim 2, wherein Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -CO2R3, -C(=O)R3 ; -(alkyl-O)k-L wherein R3 is selected from -H, -alkyl or -aryl; wherein k is 1, 2, 3, 4, 5 or 6; and wherein L is -H, -alkyl; or
Z is a substituent of Formula III
Formula III wherein m is 0, 1, 2, 3 or 4, and when m is 0, 1, 2, 3 or 4, any adjacent carbons are optionally unsaturated to form a double or triple bond; wherein Y is selected from -CH2-, -O-, -C(=O) -S-, -S(=O)-, -SO2-, -N(alkyl)-; wherein p is selected from 0, or 1 ; wherein R4 is selected from -H, or -alkyl-ONO2; wherein R5 is selected from -H, -OH, -NH2, -alkyl, -NH(alkyl), -N(alkyl)2, -ONO2, -alkyl- ONO2, -aryl, -heteroaryl, -heterocyclyl, C(=O)R3 or - CO2R3.
6 The compound of Formula I as claimed in claim 5, wherein Z is selected from -H, -alkyl, -aryl, -heteroaryl, -heterocyclyl, -CO2R3, -C(=O)R3 -(CH2CH2O)k-L, wherein R3 is selected from H, alkyl or aryl and wherein k isl, 2, 3, 4, 5 or 6; and wherein L is -H or -alkyl.
7 The compound of Formula I as claimed in claim 1 , wherein X is a compound of Formula II, n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2 and p is 0.
8 The compound of Formula I as claimed in claim 1, wherein R1 is -H, X is -ONO2; Z is -H, -alkyl or a substituent of Formula III.
9 The compound of Formula I as claimed in claim 1, wherein n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
10 The compound of Formula I as claimed in claim 1, wherein R1 is -H, X is Formula II, n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
11 The compound of Formula I as claimed in claim 1, wherein R1 is -H, X is Formula II, R2 is -CH2ONO2, n is 0, 1 or 2 and Z is a substituent of Formula III and m is 0, 1 or 2.
12 The compound of Formula I or a salt thereof as claimed in any one of claims 1 to 11 being selected from one or more of the following:
16 The compound of Formula I as claimed in claim 12 being
17 The compound of Formula I as claimed in claim 12 being
or a salt thereof.
18 The compound of Formula I as claimed in claim 12 being or a salt thereof.
19 The compound of Formula I as claimed in claim 12 being or a salt thereof.
20 The compound of Formula I as claimed in claim 12 being or a salt thereof.
21 The compound of Formula I as claimed in claim 12 being
22 The use of a compound of Formula I as claimed in any one of claims 1 to 21 for reducing the formation of methane from the digestive actions of ruminants and/or for improving ruminant performance.
23 The use of a compound of Formula I as claimed in any one of claims 1 to 21 for reducing the formation of methane from the digestive actions of ruminants.
24 The use of a compound of Formula I as claimed in any one of claims 1 to 21 for reducing the formation of methane from the digestive actions of ruminants by at least 10%.
25 The use of a compound of Formula I as claimed in any one of claims 1 to 21 for reducing the formation of methane from the digestive actions of ruminants by at least 15%.
26 The use of a compound of Formula I as claimed in any one of claims 1 to 21 for reducing the formation of methane from the digestive actions of ruminants by at least 20%.
27 A method for reducing the production of methane emanating from a ruminant and/or for improving ruminant animal performance, comprising administering orally to the ruminant an effective amount of at least one compound of Formula I or a salt thereof as claimed in any one of claims 1 to 21 to the ruminant.
28 The method as claimed in claim 27, wherein the effective amount of at least one compound of Formula I or a salt thereof is administered at least once-daily to the ruminant.
29 The method as claimed in claim 28, wherein the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 10% per day.
30 The method as claimed in claim 29, wherein the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 15% per day.
31 The method as claimed in claim 30, wherein the effective amount of at least one compound of Formula I or a salt thereof reduces the production of methane emanating from the ruminant by at least 20% per day.
32 A composition for oral administration comprising at least one compound of Formula I or a salt thereof as claimed in any one of claims 1 to 21 for reducing the production of
methane emanating from a ruminant, and the composition further including at least one agriculturally and orally acceptable excipient.
33 The composition as claimed in claim 32 being adapted for use as a feed additive.
34 The composition as claimed in claim 32 or claim 33 being adapted for use as a water additive.
35 The composition as claimed in claim 32 or claim 33 being adapted for use as a ruminant lick.
36 The composition as claimed in claim 32 being adapted for use as an oral drench.
37 The composition as claimed in claim 32 being adapted for use as a rumen bolus or capsule.
38 The composition as claimed in any one of claims 32 to 37 being adapted to reduce the production of methane emanating from the ruminant by at least 10% per day.
39 The composition as claimed in claim 38 being adapted to reduce the production of methane emanating from the ruminant by at least 15% per day.
40 The composition as claimed in claim 39 being adapted to reduce the production of methane emanating from the ruminant by at least 20% per day.
41 The composition as claimed in any one of claims 32 to 40 wherein the excipient includes one or more minerals and/or one or more vitamins.
42 The composition as claimed in claim 41 wherein the excipient includes one or more vitamins selected from vitamin A, vitamin D3, vitamin E, and vitamin K, e.g. vitamin K3, vitamin B 12, biotin and choline, vitamin B l, vitamin B2, vitamin B6, niacin, folic acid or the like.
43 The composition as claimed in claim 42 wherein the excipient includes one or more minerals selected from calcium, phosphorus, sodium, manganese, zinc, iron, copper, chlorine, sulphur, magnesium, iodine, selenium, and cobalt or the like.
44 The composition as claimed in any one of claims 32 to 43 further including sunflower oil, electrolytes such as ammonium chloride, calcium carbonates, starch, proteins or the like.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ769755 | 2020-11-10 | ||
NZ76975520 | 2020-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022103280A1 true WO2022103280A1 (en) | 2022-05-19 |
Family
ID=81601547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/NZ2021/050199 WO2022103280A1 (en) | 2020-11-10 | 2021-11-10 | Methanogen inhibitors |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022103280A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048582A1 (en) * | 2021-09-24 | 2023-03-30 | Pastoral Greenhouse Gas Research Limited | Methanogen inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0010441A1 (en) * | 1978-10-23 | 1980-04-30 | Merck & Co. Inc. | The use of symmetrically substituted pyromellitic diimides as ruminant feed additives. Compositions containing these feed additives |
EP0010440A1 (en) * | 1978-10-23 | 1980-04-30 | Merck & Co. Inc. | Pyromellitic diimides, processes for their preparation, these compounds in orally administrable form for use in increasing the feed efficiency of a ruminant animal and compositions for this purpose containing them |
US4393046A (en) * | 1981-01-30 | 1983-07-12 | Merck & Co., Inc. | Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency |
-
2021
- 2021-11-10 WO PCT/NZ2021/050199 patent/WO2022103280A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0010441A1 (en) * | 1978-10-23 | 1980-04-30 | Merck & Co. Inc. | The use of symmetrically substituted pyromellitic diimides as ruminant feed additives. Compositions containing these feed additives |
EP0010440A1 (en) * | 1978-10-23 | 1980-04-30 | Merck & Co. Inc. | Pyromellitic diimides, processes for their preparation, these compounds in orally administrable form for use in increasing the feed efficiency of a ruminant animal and compositions for this purpose containing them |
US4393046A (en) * | 1981-01-30 | 1983-07-12 | Merck & Co., Inc. | Combination of thiopeptin and other related sulfur-containing cyclic polypeptide antibiotics with rumen-active diimides to improve ruminant feed efficiency |
Non-Patent Citations (4)
Title |
---|
DATABASE REGISTRY CAS; 13 April 1990 (1990-04-13), "Benzo[1,2-c:4,5-c']dipyrrole-1,3,5,7(2H,6H)-tetrone, 2,6-dihexyl-, radical ion(1-) (9CI)", XP055939393, retrieved from STN Database accession no. RN 126426-84-4 * |
DATABASE REGISTRY CAS; 18 July 2001 (2001-07-18), "Benzo[1,2-c:4,5-c']dipyrrole-1,3,5,7(2H,6H)-tetrone, 2,7-bis(3-phenylpropyl)- (9CI)", XP055939391, retrieved from STN Database accession no. RN 346634-67-1 * |
DATABASE REGISTRY CAS; 21 August 2007 (2007-08-21), "Pyridinium, 1-[2-(6-hexyl-3,5,6,7-tetrahydro-1,3,5,7-tetraoxobenzo[1,2- c:4,5-c']dipyrrol-2(1H)-yl)ethyl]-", XP055939389, retrieved from STN Database accession no. RN 945229-78-7 * |
LINN BRUCE O., LYNN M. PAEGE, PATRICK J. DOHERTY, RICHARD J. BOCHIS, FRANK S. WAKSMUNSKI, PETER KULSA, AND MICHAEL H. FISHER : "A Series of Pyromellitic Diimides That Improve the Efficiency of Rumen Fermentation", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 30, 1 January 1982 (1982-01-01), pages 1236 - 1242, XP055939398, Retrieved from the Internet <URL:https://pubs.acs.org/doi/pdf/10.1021/jf00114a058> [retrieved on 20220706] * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023048582A1 (en) * | 2021-09-24 | 2023-03-30 | Pastoral Greenhouse Gas Research Limited | Methanogen inhibitors |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SU1436878A3 (en) | Method of producing substituted nitrogen-containing bicyclic compounds or acid-additive salts thereof or stereoisomers thereof or mixture of stereoisomers | |
AU2001268089B2 (en) | Adenosine A2a receptor antagonists | |
AU2014220357A1 (en) | Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of Janus- related Kinases (JAK) | |
AU6268794A (en) | 2-benzyl-polycyclic guanine derivatives and process for preparing them | |
KR101832396B1 (en) | Method for the synthesis of ergothioneine and the like | |
KR20110043697A (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
KR20170018063A (en) | Synthesis of polycyclic-carbamoylpyridone compounds | |
JP2013505295A (en) | Compound that selectively modulates CB2 receptor | |
WO2022103280A1 (en) | Methanogen inhibitors | |
US4139563A (en) | α-ACETYLENIC DERIVATIVES OF AMINES | |
SU1757464A3 (en) | Method for preparation of amino derivatives of benzoxazolone | |
JPH0469155B2 (en) | ||
US11708365B2 (en) | Processes for preparing TPH1 inhibitors | |
WO2022103281A1 (en) | Methanogen inhibitors | |
SU950188A3 (en) | Process for producing derivatives of 4(5)-mercaptomethylimidazoles | |
SU558644A3 (en) | The method of obtaining imidazoles or their salts | |
US20030153728A1 (en) | Modified safe and efficient process for the environmentally friendly synthesis of lmidoesters | |
CA3232111A1 (en) | Methanogen inhibitors | |
US11078163B2 (en) | Processes for the synthesis of substituted urea compounds | |
AU2019281584B2 (en) | Selective A2A receptor antagonist | |
JP7275053B2 (en) | Compounds as GLS1 inhibitors | |
PL170798B1 (en) | Method of obtaining crystalline addition salts of the both diasteromers of 1-(2,2-dimethyl-propionyloxy)-ethyl 3-cephem-4-carboxylic ester | |
CN114127077B (en) | Tetrafused ring compounds useful as Cdc7 inhibitors | |
WO2024041397A1 (en) | Jak1/jak2/tyk2 inhibitors for topical treatment of dermatological diseases | |
Sadchikova et al. | Synthesis and properties of 5-diazoimidazoles and imidazolyl-5-diazonium salts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21892424 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21892424 Country of ref document: EP Kind code of ref document: A1 |